<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd"><coredata><prism:url>http://api.elsevier.com/content/article/pii/S0168365913009036</prism:url><dc:identifier>doi:10.1016/j.jconrel.2013.11.014</dc:identifier><eid>1-s2.0-S0168365913009036</eid><prism:doi>10.1016/j.jconrel.2013.11.014</prism:doi><pii>S0168-3659(13)00903-6</pii><dc:title>PEGylation improves the receptor-mediated transfection efficiency of peptide-targeted, self-assembling, anionic nanocomplexes </dc:title><prism:publicationName>Journal of Controlled Release</prism:publicationName><prism:aggregationType>Journal</prism:aggregationType><prism:issn>01683659</prism:issn><prism:volume>174</prism:volume><prism:startingPage>177</prism:startingPage><prism:endingPage>187</prism:endingPage><prism:pageRange>177-187</prism:pageRange><dc:format>text/xml</dc:format><prism:coverDate>2014-01-28</prism:coverDate><prism:coverDisplayDate>28 January 2014</prism:coverDisplayDate><prism:copyright>Copyright © 2013 The Authors. Published by Elsevier B.V.</prism:copyright><prism:publisher>The Authors. Published by Elsevier B.V.</prism:publisher><dc:creator>Tagalakis, Aristides D.</dc:creator><dc:creator>Kenny, Gavin D.</dc:creator><dc:creator>Bienemann, Alison S.</dc:creator><dc:creator>McCarthy, David</dc:creator><dc:creator>Munye, Mustafa M.</dc:creator><dc:creator>Taylor, Hannah</dc:creator><dc:creator>Wyatt, Marcella J.</dc:creator><dc:creator>Lythgoe, Mark F.</dc:creator><dc:creator>White, Edward A.</dc:creator><dc:creator>Hart, Stephen L.</dc:creator><dc:description>AbstractNon-viral vector formulations comprise typically complexes of nucleic acids with cationic polymers or lipids. However, for in vivo applications cationic formulations suffer from problems of poor tissue penetration, non-specific binding to cells, interaction with serum proteins and cell adhesion molecules and can lead to inflammatory responses. Anionic formulations may provide a solution to these problems but they have not been developed to the same extent as cationic formulations due to difficulties of nucleic acid packaging and poor transfection efficiency. We have developed novel PEGylated, anionic nanocomplexes containing cationic targeting peptides that act as a bridge between PEGylated anionic liposomes and plasmid DNA. At optimized ratios, the components self-assemble into anionic nanocomplexes with a high packaging efficiency of plasmid DNA. Anionic PEGylated nanocomplexes were resistant to aggregation in serum and transfected cells with a far higher degree of receptor-targeted specificity than their homologous non-PEGylated anionic and cationic counterparts. Gadolinium-labeled, anionic nanoparticles, administered directly to the brain by convection-enhanced delivery displayed improved tissue penetration and dispersal as well as more widespread cellular transfection than cationic formulations. Anionic PEGylated nanocomplexes have widespread potential for in vivo gene therapy due to their targeted transfection efficiency and ability to penetrate tissues.</dc:description><openaccess>1</openaccess><openaccessArticle>true</openaccessArticle><openaccessType>Full</openaccessType><openArchiveArticle>false</openArchiveArticle><openaccessSponsorName>Engineering and Physical Sciences Research Council</openaccessSponsorName><openaccessSponsorType>FundingBody</openaccessSponsorType><openaccessUserLicense>http://creativecommons.org/licenses/by/3.0/</openaccessUserLicense><dcterms:subject>Gene therapy</dcterms:subject><dcterms:subject>Targeted</dcterms:subject><dcterms:subject>Anionic</dcterms:subject><dcterms:subject>Nanoparticle</dcterms:subject><dcterms:subject>MRI</dcterms:subject><dcterms:subject>Self-assembling</dcterms:subject><link rel="self" href="http://api.elsevier.com/content/article/pii/S0168365913009036"/><link rel="scidir" href="http://www.sciencedirect.com/science/article/pii/S0168365913009036"/></coredata><objects><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="100752">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-mmc1.docx?httpAccept=%2A%2F%2A</object><object ref="gr9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2537" height="1917" size="698667">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1612" height="1413" size="211436">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1733" height="3861" size="470876">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3157" height="3838" size="1350810">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1004" height="1258" size="314753">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3547" height="3729" size="677875">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="833" height="2626" size="471859">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1518" height="1058" size="122752">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3346" height="2430" size="596793">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="961" height="886" size="158387">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="573" height="433" size="67548">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="364" height="319" size="38527">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="391" height="871" size="66489">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="867" size="130435">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="378" height="474" size="70360">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="801" height="842" size="94825">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="313" height="987" size="84196">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="343" height="239" size="22681">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="756" height="549" size="86360">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="217" height="200" size="23255">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="217" height="164" size="14923">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="187" height="164" size="5412">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="73" height="163" size="2511">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="135" height="164" size="8270">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="131" height="164" size="8808">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="156" height="164" size="4090">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="52" height="164" size="2581">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="153" size="3202">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="159" size="5427">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="178" height="164" size="6732">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913009036-fx1.sml?httpAccept=%2A%2F%2A</object></objects><scopus-id>84890284256</scopus-id><scopus-eid>2-s2.0-84890284256</scopus-eid><pubmed-id>24269968</pubmed-id><link rel="abstract" href="http://api.elsevier.com/content/abstract/scopus_id/84890284256"/><originalText><xocs:doc xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd" xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://be-prod3a/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta><xocs:content-family>serial</xocs:content-family><xocs:content-type>JL</xocs:content-type><xocs:cid>271103</xocs:cid><xocs:ssids><xocs:ssid type="alllist">291210</xocs:ssid><xocs:ssid type="subj">291681</xocs:ssid><xocs:ssid type="subj">291789</xocs:ssid><xocs:ssid type="content">31</xocs:ssid><xocs:ssid type="oa">90</xocs:ssid></xocs:ssids><xocs:srctitle>Journal of Controlled Release</xocs:srctitle><xocs:normalized-srctitle>JOURNALCONTROLLEDRELEASE</xocs:normalized-srctitle><xocs:orig-load-date yyyymmdd="20131122">2013-11-22</xocs:orig-load-date><xocs:available-online-date yyyymmdd="20131122">2013-11-22</xocs:available-online-date><xocs:ew-transaction-id>2014-10-01T13:52:14</xocs:ew-transaction-id><xocs:eid>1-s2.0-S0168365913009036</xocs:eid><xocs:pii-formatted>S0168-3659(13)00903-6</xocs:pii-formatted><xocs:pii-unformatted>S0168365913009036</xocs:pii-unformatted><xocs:doi>10.1016/j.jconrel.2013.11.014</xocs:doi><xocs:item-stage>S300</xocs:item-stage><xocs:item-version-number>S300.4</xocs:item-version-number><xocs:item-weight>FULL-TEXT</xocs:item-weight><xocs:hub-eid>1-s2.0-S0168365913X00227</xocs:hub-eid><xocs:timestamp yyyymmdd="20150514">2015-05-14T05:17:02.743021-04:00</xocs:timestamp><xocs:dco>0</xocs:dco><xocs:tomb>0</xocs:tomb><xocs:date-search-begin>20140128</xocs:date-search-begin><xocs:year-nav>2014</xocs:year-nav><xocs:indexeddate epoch="1385078400">2013-11-22T00:00:00Z</xocs:indexeddate><xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid fundingbodyid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight oauserlicense openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder sponsoredaccesstype srctitle srctitlenorm srctype ssids alllist content oa subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil articletitle auth authfirstini authfull authkeywords authlast grantnumber grantsponsor primabst ref specialabst</xocs:articleinfo><xocs:issns><xocs:issn-primary-formatted>0168-3659</xocs:issn-primary-formatted><xocs:issn-primary-unformatted>01683659</xocs:issn-primary-unformatted></xocs:issns><xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type><xocs:funding-body-id>EPSRCPP</xocs:funding-body-id><xocs:crossmark is-crossmark="1">true</xocs:crossmark><xocs:vol-first>174</xocs:vol-first><xocs:volume-list><xocs:volume>174</xocs:volume></xocs:volume-list><xocs:suppl>C</xocs:suppl><xocs:vol-iss-suppl-text>Volume 174</xocs:vol-iss-suppl-text><xocs:sort-order>16</xocs:sort-order><xocs:first-fp>177</xocs:first-fp><xocs:last-lp>187</xocs:last-lp><xocs:pages><xocs:first-page>177</xocs:first-page><xocs:last-page>187</xocs:last-page></xocs:pages><xocs:cover-date-orig><xocs:start-date>20140128</xocs:start-date></xocs:cover-date-orig><xocs:cover-date-text>28 January 2014</xocs:cover-date-text><xocs:cover-date-start>2014-01-28</xocs:cover-date-start><xocs:cover-date-year>2014</xocs:cover-date-year><xocs:hub-sec><xocs:hub-sec-title>Gene Delivery</xocs:hub-sec-title></xocs:hub-sec><xocs:document-type>article</xocs:document-type><xocs:document-subtype>fla</xocs:document-subtype><xocs:copyright-line>Copyright © 2013 The Authors. Published by Elsevier B.V.</xocs:copyright-line><xocs:normalized-article-title>PEGYLATIONIMPROVESRECEPTORMEDIATEDTRANSFECTIONEFFICIENCYPEPTIDETARGETEDSELFASSEMBLINGANIONICNANOCOMPLEXES</xocs:normalized-article-title><xocs:normalized-first-auth-surname>TAGALAKIS</xocs:normalized-first-auth-surname><xocs:normalized-first-auth-initial>A</xocs:normalized-first-auth-initial><xocs:item-toc><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>1</xocs:item-toc-label><xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2</xocs:item-toc-label><xocs:item-toc-section-title>Materials and methods</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.1</xocs:item-toc-label><xocs:item-toc-section-title>Materials</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.2</xocs:item-toc-label><xocs:item-toc-section-title>Liposome formulation</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.3</xocs:item-toc-label><xocs:item-toc-section-title>Nanoparticle formulation</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.4</xocs:item-toc-label><xocs:item-toc-section-title><ce:italic>In vitro</ce:italic> transfections</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.5</xocs:item-toc-label><xocs:item-toc-section-title>Particle size and charge measurements</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.6</xocs:item-toc-label><xocs:item-toc-section-title>Turbidity assay</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.7</xocs:item-toc-label><xocs:item-toc-section-title>PicoGreen fluorescence quenching experiments</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.8</xocs:item-toc-label><xocs:item-toc-section-title>Transmission electron microscopy (TEM)</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.9</xocs:item-toc-label><xocs:item-toc-section-title>Cell proliferation assay</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.10</xocs:item-toc-label><xocs:item-toc-section-title><ce:italic>In vivo</ce:italic> CED procedures</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.11</xocs:item-toc-label><xocs:item-toc-section-title>MRI</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.12</xocs:item-toc-label><xocs:item-toc-section-title>Histological assessment and cell staining</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.13</xocs:item-toc-label><xocs:item-toc-section-title>qRT-PCR</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.14</xocs:item-toc-label><xocs:item-toc-section-title>Statistical analysis</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3</xocs:item-toc-label><xocs:item-toc-section-title>Results</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.1</xocs:item-toc-label><xocs:item-toc-section-title>Development and characterization of anionic nanoparticles</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.2</xocs:item-toc-label><xocs:item-toc-section-title>Enhanced targeted cell transfection efficiency and viability of anionic PDLs</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.3</xocs:item-toc-label><xocs:item-toc-section-title><ce:italic>In vivo</ce:italic> administration by CED of anionic PDLs demonstrated significant brain distribution and transgene expression</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>4</xocs:item-toc-label><xocs:item-toc-section-title>Discussion</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>5</xocs:item-toc-label><xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:acknowledgment"><xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:bibliography"><xocs:item-toc-section-title>References</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc><xocs:references><xocs:ref-info refid="rf0005"><xocs:ref-normalized-surname>GLOVER</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>299</xocs:ref-first-fp><xocs:ref-last-lp>310</xocs:ref-last-lp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0010"><xocs:ref-normalized-surname>SCHMIDTWOLF</xocs:ref-normalized-surname><xocs:ref-pub-year>2003</xocs:ref-pub-year><xocs:ref-first-fp>67</xocs:ref-first-fp><xocs:ref-last-lp>72</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0015"><xocs:ref-normalized-surname>ALIABADI</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>2546</xocs:ref-first-fp><xocs:ref-last-lp>2569</xocs:ref-last-lp><xocs:ref-normalized-initial>H</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0020"><xocs:ref-normalized-surname>ELSABAHY</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>235</xocs:ref-first-fp><xocs:ref-last-lp>244</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0025"><xocs:ref-normalized-surname>PEZZOLI</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>82</xocs:ref-first-fp><xocs:ref-last-lp>91</xocs:ref-last-lp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0030"><xocs:ref-normalized-surname>SCHOLZ</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>554</xocs:ref-first-fp><xocs:ref-last-lp>565</xocs:ref-last-lp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0035"><xocs:ref-normalized-surname>MAHATO</xocs:ref-normalized-surname><xocs:ref-pub-year>1997</xocs:ref-pub-year><xocs:ref-first-fp>853</xocs:ref-first-fp><xocs:ref-last-lp>859</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0040"><xocs:ref-normalized-surname>MINTZER</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>259</xocs:ref-first-fp><xocs:ref-last-lp>302</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0045"><xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname><xocs:ref-pub-year>2013</xocs:ref-pub-year><xocs:ref-first-fp>46</xocs:ref-first-fp><xocs:ref-last-lp>60</xocs:ref-last-lp><xocs:ref-normalized-initial>W</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0050"><xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>4285</xocs:ref-first-fp><xocs:ref-last-lp>4295</xocs:ref-last-lp><xocs:ref-normalized-initial>F</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0055"><xocs:ref-normalized-surname>MISHRA</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>97</xocs:ref-first-fp><xocs:ref-last-lp>111</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0060"><xocs:ref-normalized-surname>BALAZS</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>326497</xocs:ref-first-fp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0065"><xocs:ref-normalized-surname>CHIARAMONI</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>191</xocs:ref-first-fp><xocs:ref-last-lp>201</xocs:ref-last-lp><xocs:ref-normalized-initial>N</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0070"><xocs:ref-normalized-surname>PATIL</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>1</xocs:ref-first-fp><xocs:ref-last-lp>11</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0075"><xocs:ref-normalized-surname>FOGED</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>160</xocs:ref-first-fp><xocs:ref-last-lp>166</xocs:ref-last-lp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0080"><xocs:ref-normalized-surname>KAPOOR</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>1603</xocs:ref-first-fp><xocs:ref-last-lp>1612</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0085"><xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>108</xocs:ref-first-fp><xocs:ref-last-lp>114</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0090"><xocs:ref-normalized-surname>PATIL</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>13</xocs:ref-first-fp><xocs:ref-last-lp>22</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0095"><xocs:ref-normalized-surname>SRINIVASAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>62</xocs:ref-first-fp><xocs:ref-last-lp>70</xocs:ref-last-lp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0100"><xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>22639</xocs:ref-first-fp><xocs:ref-last-lp>22650</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0105"><xocs:ref-normalized-surname>SUN</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>668</xocs:ref-first-fp><xocs:ref-last-lp>678</xocs:ref-last-lp><xocs:ref-normalized-initial>P</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0110"><xocs:ref-normalized-surname>YUAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>224</xocs:ref-first-fp><xocs:ref-last-lp>231</xocs:ref-last-lp><xocs:ref-normalized-initial>H</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0115"><xocs:ref-normalized-surname>HARRIS</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>998</xocs:ref-first-fp><xocs:ref-last-lp>1006</xocs:ref-last-lp><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0120"><xocs:ref-normalized-surname>SCHLEGEL</xocs:ref-normalized-surname><xocs:ref-pub-year>2013</xocs:ref-pub-year><xocs:ref-first-fp>1</xocs:ref-first-fp><xocs:ref-last-lp>8</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0125"><xocs:ref-normalized-surname>MIGNET</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>194</xocs:ref-first-fp><xocs:ref-last-lp>201</xocs:ref-last-lp><xocs:ref-normalized-initial>N</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0130"><xocs:ref-normalized-surname>MANUNTA</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>e26768</xocs:ref-first-fp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0135"><xocs:ref-normalized-surname>TAGALAKIS</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>907</xocs:ref-first-fp><xocs:ref-last-lp>915</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0140"><xocs:ref-normalized-surname>GROSSE</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>2301</xocs:ref-first-fp><xocs:ref-last-lp>2313</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0145"><xocs:ref-normalized-surname>KENNY</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>7241</xocs:ref-first-fp><xocs:ref-last-lp>7250</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0150"><xocs:ref-normalized-surname>TAGALAKIS</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>1370</xocs:ref-first-fp><xocs:ref-last-lp>1376</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0155"><xocs:ref-normalized-surname>IRVINE</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>508</xocs:ref-first-fp><xocs:ref-last-lp>515</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0160"><xocs:ref-normalized-surname>MENG</xocs:ref-normalized-surname><xocs:ref-pub-year>2013</xocs:ref-pub-year><xocs:ref-first-fp>979</xocs:ref-first-fp><xocs:ref-last-lp>986</xocs:ref-last-lp><xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0165"><xocs:ref-normalized-surname>KENNY</xocs:ref-normalized-surname><xocs:ref-pub-year>2013</xocs:ref-pub-year><xocs:ref-first-fp>9190</xocs:ref-first-fp><xocs:ref-last-lp>9200</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0170"><xocs:ref-normalized-surname>TAGALAKIS</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>6302</xocs:ref-first-fp><xocs:ref-last-lp>6315</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0175"><xocs:ref-normalized-surname>WRITER</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>185</xocs:ref-first-fp><xocs:ref-last-lp>193</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0180"><xocs:ref-normalized-surname>TAGALAKIS</xocs:ref-normalized-surname><xocs:ref-pub-year>2013</xocs:ref-pub-year><xocs:ref-first-fp>761</xocs:ref-first-fp><xocs:ref-last-lp>770</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0185"><xocs:ref-normalized-surname>BOBO</xocs:ref-normalized-surname><xocs:ref-pub-year>1994</xocs:ref-pub-year><xocs:ref-first-fp>2076</xocs:ref-first-fp><xocs:ref-last-lp>2080</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0190"><xocs:ref-normalized-surname>CARSON</xocs:ref-normalized-surname><xocs:ref-pub-year>2002</xocs:ref-pub-year><xocs:ref-first-fp>151</xocs:ref-first-fp><xocs:ref-last-lp>158</xocs:ref-last-lp><xocs:ref-normalized-initial>B</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0195"><xocs:ref-normalized-surname>GILL</xocs:ref-normalized-surname><xocs:ref-pub-year>2003</xocs:ref-pub-year><xocs:ref-first-fp>589</xocs:ref-first-fp><xocs:ref-last-lp>595</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0200"><xocs:ref-normalized-surname>GROOTHUIS</xocs:ref-normalized-surname><xocs:ref-pub-year>1999</xocs:ref-pub-year><xocs:ref-first-fp>321</xocs:ref-first-fp><xocs:ref-last-lp>331</xocs:ref-last-lp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0205"><xocs:ref-normalized-surname>MARDOR</xocs:ref-normalized-surname><xocs:ref-pub-year>2001</xocs:ref-pub-year><xocs:ref-first-fp>4971</xocs:ref-first-fp><xocs:ref-last-lp>4973</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0210"><xocs:ref-normalized-surname>VOGES</xocs:ref-normalized-surname><xocs:ref-pub-year>2003</xocs:ref-pub-year><xocs:ref-first-fp>479</xocs:ref-first-fp><xocs:ref-last-lp>487</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0215"><xocs:ref-normalized-surname>WHITE</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>237</xocs:ref-first-fp><xocs:ref-last-lp>251</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0220"><xocs:ref-normalized-surname>KIELAR</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>7836</xocs:ref-first-fp><xocs:ref-last-lp>7837</xocs:ref-last-lp><xocs:ref-normalized-initial>F</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0225"><xocs:ref-normalized-surname>JOST</xocs:ref-normalized-surname><xocs:ref-pub-year>2001</xocs:ref-pub-year><xocs:ref-first-fp>263</xocs:ref-first-fp><xocs:ref-last-lp>269</xocs:ref-last-lp><xocs:ref-normalized-initial>P</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0230"><xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>143</xocs:ref-first-fp><xocs:ref-last-lp>157</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0235"><xocs:ref-normalized-surname>PENFIELD</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>654</xocs:ref-first-fp><xocs:ref-last-lp>668</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0240"><xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname><xocs:ref-pub-year>1996</xocs:ref-pub-year><xocs:ref-first-fp>8481</xocs:ref-first-fp><xocs:ref-last-lp>8487</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0245"><xocs:ref-normalized-surname>LORENZI</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>1077</xocs:ref-first-fp><xocs:ref-last-lp>1085</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0250"><xocs:ref-normalized-surname>SUN</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>797</xocs:ref-first-fp><xocs:ref-last-lp>805</xocs:ref-last-lp><xocs:ref-normalized-initial>X</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0255"><xocs:ref-normalized-surname>YE</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>285708</xocs:ref-first-fp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0260"><xocs:ref-normalized-surname>GREEN</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>874</xocs:ref-first-fp><xocs:ref-last-lp>879</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0265"><xocs:ref-normalized-surname>HE</xocs:ref-normalized-surname><xocs:ref-pub-year>2013</xocs:ref-pub-year><xocs:ref-first-fp>1235</xocs:ref-first-fp><xocs:ref-last-lp>1245</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0270"><xocs:ref-normalized-surname>LIAO</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>3306</xocs:ref-first-fp><xocs:ref-last-lp>3315</xocs:ref-last-lp><xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0275"><xocs:ref-normalized-surname>TIAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>47</xocs:ref-first-fp><xocs:ref-last-lp>53</xocs:ref-last-lp><xocs:ref-normalized-initial>H</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0280"><xocs:ref-normalized-surname>MACKAY</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>893</xocs:ref-first-fp><xocs:ref-last-lp>900</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0285"><xocs:ref-normalized-surname>KAPOOR</xocs:ref-normalized-surname><xocs:ref-pub-year>2013</xocs:ref-pub-year><xocs:ref-first-fp>1161</xocs:ref-first-fp><xocs:ref-last-lp>1175</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0290"><xocs:ref-normalized-surname>LAVIGNE</xocs:ref-normalized-surname><xocs:ref-pub-year>2013</xocs:ref-pub-year><xocs:ref-first-fp>973</xocs:ref-first-fp><xocs:ref-last-lp>985</xocs:ref-last-lp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0295"><xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname><xocs:ref-pub-year>1997</xocs:ref-pub-year><xocs:ref-first-fp>950</xocs:ref-first-fp><xocs:ref-last-lp>960</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0300"><xocs:ref-normalized-surname>CULLIS</xocs:ref-normalized-surname><xocs:ref-pub-year>1998</xocs:ref-pub-year><xocs:ref-first-fp>3</xocs:ref-first-fp><xocs:ref-last-lp>17</xocs:ref-last-lp><xocs:ref-normalized-initial>P</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0305"><xocs:ref-normalized-surname>BELLAVANCE</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>251</xocs:ref-first-fp><xocs:ref-last-lp>259</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0310"><xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname><xocs:ref-pub-year>2002</xocs:ref-pub-year><xocs:ref-first-fp>976</xocs:ref-first-fp><xocs:ref-last-lp>983</xocs:ref-last-lp><xocs:ref-normalized-initial>W</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0315"><xocs:ref-normalized-surname>MACKAY</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>139</xocs:ref-first-fp><xocs:ref-last-lp>153</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info></xocs:references><xocs:refkeys><xocs:refkey3>TAGALAKISX2014X177</xocs:refkey3><xocs:refkey4lp>TAGALAKISX2014X177X187</xocs:refkey4lp><xocs:refkey4ai>TAGALAKISX2014X177XA</xocs:refkey4ai><xocs:refkey5>TAGALAKISX2014X177X187XA</xocs:refkey5></xocs:refkeys><xocs:open-access><xocs:oa-article-status is-open-access="1" is-open-archive="0">Full</xocs:oa-article-status><xocs:oa-access-effective-date>2013-11-19T05:07:52Z</xocs:oa-access-effective-date><xocs:oa-sponsor><xocs:oa-sponsor-type>FundingBody</xocs:oa-sponsor-type><xocs:oa-sponsor-name>Engineering and Physical Sciences Research Council</xocs:oa-sponsor-name></xocs:oa-sponsor><xocs:oa-user-license>http://creativecommons.org/licenses/by/3.0/</xocs:oa-user-license></xocs:open-access><xocs:attachment-metadata-doc><xocs:attachment-set-type>item</xocs:attachment-set-type><xocs:pii-formatted>S0168-3659(13)00903-6</xocs:pii-formatted><xocs:pii-unformatted>S0168365913009036</xocs:pii-unformatted><xocs:eid>1-s2.0-S0168365913009036</xocs:eid><xocs:doi>10.1016/j.jconrel.2013.11.014</xocs:doi><xocs:cid>271103</xocs:cid><xocs:timestamp>2014-10-02T08:10:24.871113-04:00</xocs:timestamp><xocs:cover-date-start>2014-01-28</xocs:cover-date-start><xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type><xocs:funding-body-id>EPSRCPP</xocs:funding-body-id><xocs:attachments><xocs:web-pdf><xocs:attachment-eid>1-s2.0-S0168365913009036-main.pdf</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/MAIN/application/pdf/3a7e9480981dcb1cc3a4195956a8f98d/main.pdf</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/MAIN/application/pdf/3a7e9480981dcb1cc3a4195956a8f98d/main.pdf</xocs:ucs-locator><xocs:filename>main.pdf</xocs:filename><xocs:extension>pdf</xocs:extension><xocs:pdf-optimized>true</xocs:pdf-optimized><xocs:filesize>1666813</xocs:filesize><xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose><xocs:web-pdf-page-count>11</xocs:web-pdf-page-count><xocs:web-pdf-images><xocs:web-pdf-image><xocs:attachment-eid>1-s2.0-S0168365913009036-main_1.png</xocs:attachment-eid><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/PREVIEW/image/png/006f6fd443804d3d76efb9c3b65d868c/main_1.png</xocs:ucs-locator><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/PREVIEW/image/png/006f6fd443804d3d76efb9c3b65d868c/main_1.png</xocs:ucs-locator><xocs:filename>main_1.png</xocs:filename><xocs:extension>png</xocs:extension><xocs:filesize>62052</xocs:filesize><xocs:pixel-height>849</xocs:pixel-height><xocs:pixel-width>656</xocs:pixel-width><xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type><xocs:pdf-page-num>1</xocs:pdf-page-num></xocs:web-pdf-image></xocs:web-pdf-images></xocs:web-pdf><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-mmc1.docx</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/mmc1/MAIN/application/msword/899a68e48907455839f7fa885e1bbc7d/mmc1.docx</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/mmc1/MAIN/application/msword/899a68e48907455839f7fa885e1bbc7d/mmc1.docx</xocs:ucs-locator><xocs:file-basename>mmc1</xocs:file-basename><xocs:filename>mmc1.docx</xocs:filename><xocs:extension>docx</xocs:extension><xocs:filesize>100752</xocs:filesize><xocs:attachment-type>APPLICATION</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr9_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr9/HIGHRES/image/jpeg/5da2d3fb391b49f004a460c298613aca/gr9_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr9/HIGHRES/image/jpeg/5da2d3fb391b49f004a460c298613aca/gr9_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr9</xocs:file-basename><xocs:filename>gr9_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>698667</xocs:filesize><xocs:pixel-height>1917</xocs:pixel-height><xocs:pixel-width>2537</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr8_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr8/HIGHRES/image/jpeg/b5454bc15226a7e6fd66f5e952e7eec4/gr8_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr8/HIGHRES/image/jpeg/b5454bc15226a7e6fd66f5e952e7eec4/gr8_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr8</xocs:file-basename><xocs:filename>gr8_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>211436</xocs:filesize><xocs:pixel-height>1413</xocs:pixel-height><xocs:pixel-width>1612</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr7_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr7/HIGHRES/image/jpeg/c64624cbb1a8caf74e9d40c9ff70c2a0/gr7_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr7/HIGHRES/image/jpeg/c64624cbb1a8caf74e9d40c9ff70c2a0/gr7_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr7</xocs:file-basename><xocs:filename>gr7_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>470876</xocs:filesize><xocs:pixel-height>3861</xocs:pixel-height><xocs:pixel-width>1733</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr6_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr6/HIGHRES/image/jpeg/a5d9ee8cec18d16616d0c3fb9d4f0c9c/gr6_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr6/HIGHRES/image/jpeg/a5d9ee8cec18d16616d0c3fb9d4f0c9c/gr6_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr6</xocs:file-basename><xocs:filename>gr6_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>1350810</xocs:filesize><xocs:pixel-height>3838</xocs:pixel-height><xocs:pixel-width>3157</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr5_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr5/HIGHRES/image/jpeg/d677ed69885cdfdd0944094a8cb4a56b/gr5_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr5/HIGHRES/image/jpeg/d677ed69885cdfdd0944094a8cb4a56b/gr5_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>314753</xocs:filesize><xocs:pixel-height>1258</xocs:pixel-height><xocs:pixel-width>1004</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr4_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr4/HIGHRES/image/jpeg/91174fb24e4b30a3d4ab76cde2cdcc86/gr4_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr4/HIGHRES/image/jpeg/91174fb24e4b30a3d4ab76cde2cdcc86/gr4_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>677875</xocs:filesize><xocs:pixel-height>3729</xocs:pixel-height><xocs:pixel-width>3547</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr3_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr3/HIGHRES/image/jpeg/92b58e2a9295635914bde99d4bd07513/gr3_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr3/HIGHRES/image/jpeg/92b58e2a9295635914bde99d4bd07513/gr3_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>471859</xocs:filesize><xocs:pixel-height>2626</xocs:pixel-height><xocs:pixel-width>833</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr2_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr2/HIGHRES/image/jpeg/9ad7570b0874830b50e8ff8e8d45ba72/gr2_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr2/HIGHRES/image/jpeg/9ad7570b0874830b50e8ff8e8d45ba72/gr2_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>122752</xocs:filesize><xocs:pixel-height>1058</xocs:pixel-height><xocs:pixel-width>1518</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr1_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr1/HIGHRES/image/jpeg/c6fe0da1c608884865d58890973a3393/gr1_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr1/HIGHRES/image/jpeg/c6fe0da1c608884865d58890973a3393/gr1_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>596793</xocs:filesize><xocs:pixel-height>2430</xocs:pixel-height><xocs:pixel-width>3346</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-fx1_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/fx1/HIGHRES/image/jpeg/e801ce9a79d2c300a8e05a1f79f91d9d/fx1_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/fx1/HIGHRES/image/jpeg/e801ce9a79d2c300a8e05a1f79f91d9d/fx1_lrg.jpg</xocs:ucs-locator><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>158387</xocs:filesize><xocs:pixel-height>886</xocs:pixel-height><xocs:pixel-width>961</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr9.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr9/DOWNSAMPLED/image/jpeg/49a63fbbb9b9c223cc659184277baf56/gr9.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr9/DOWNSAMPLED/image/jpeg/49a63fbbb9b9c223cc659184277baf56/gr9.jpg</xocs:ucs-locator><xocs:file-basename>gr9</xocs:file-basename><xocs:filename>gr9.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>67548</xocs:filesize><xocs:pixel-height>433</xocs:pixel-height><xocs:pixel-width>573</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr8.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr8/DOWNSAMPLED/image/jpeg/d429d70e27a70d70f9a981ab5ff3ad1e/gr8.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr8/DOWNSAMPLED/image/jpeg/d429d70e27a70d70f9a981ab5ff3ad1e/gr8.jpg</xocs:ucs-locator><xocs:file-basename>gr8</xocs:file-basename><xocs:filename>gr8.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>38527</xocs:filesize><xocs:pixel-height>319</xocs:pixel-height><xocs:pixel-width>364</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr7.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr7/DOWNSAMPLED/image/jpeg/b895a14ce8ef3967c3d6da281cf46f1e/gr7.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr7/DOWNSAMPLED/image/jpeg/b895a14ce8ef3967c3d6da281cf46f1e/gr7.jpg</xocs:ucs-locator><xocs:file-basename>gr7</xocs:file-basename><xocs:filename>gr7.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>66489</xocs:filesize><xocs:pixel-height>871</xocs:pixel-height><xocs:pixel-width>391</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr6.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr6/DOWNSAMPLED/image/jpeg/4a01386c591ab301a82a76d1f256f6e3/gr6.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr6/DOWNSAMPLED/image/jpeg/4a01386c591ab301a82a76d1f256f6e3/gr6.jpg</xocs:ucs-locator><xocs:file-basename>gr6</xocs:file-basename><xocs:filename>gr6.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>130435</xocs:filesize><xocs:pixel-height>867</xocs:pixel-height><xocs:pixel-width>713</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr5.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr5/DOWNSAMPLED/image/jpeg/8cf92859ad3435427c18eb08e6e832b3/gr5.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr5/DOWNSAMPLED/image/jpeg/8cf92859ad3435427c18eb08e6e832b3/gr5.jpg</xocs:ucs-locator><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>70360</xocs:filesize><xocs:pixel-height>474</xocs:pixel-height><xocs:pixel-width>378</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr4.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr4/DOWNSAMPLED/image/jpeg/600a6304f7b93e4194d47837bab51a95/gr4.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr4/DOWNSAMPLED/image/jpeg/600a6304f7b93e4194d47837bab51a95/gr4.jpg</xocs:ucs-locator><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>94825</xocs:filesize><xocs:pixel-height>842</xocs:pixel-height><xocs:pixel-width>801</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr3.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr3/DOWNSAMPLED/image/jpeg/203737416b279dcd709c05b1426cfab2/gr3.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr3/DOWNSAMPLED/image/jpeg/203737416b279dcd709c05b1426cfab2/gr3.jpg</xocs:ucs-locator><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>84196</xocs:filesize><xocs:pixel-height>987</xocs:pixel-height><xocs:pixel-width>313</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr2.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr2/DOWNSAMPLED/image/jpeg/f9e75791656fb2e8d44f82967d0aae00/gr2.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr2/DOWNSAMPLED/image/jpeg/f9e75791656fb2e8d44f82967d0aae00/gr2.jpg</xocs:ucs-locator><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>22681</xocs:filesize><xocs:pixel-height>239</xocs:pixel-height><xocs:pixel-width>343</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr1.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr1/DOWNSAMPLED/image/jpeg/cc36610afa4bb093cc021967308c9b95/gr1.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr1/DOWNSAMPLED/image/jpeg/cc36610afa4bb093cc021967308c9b95/gr1.jpg</xocs:ucs-locator><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>86360</xocs:filesize><xocs:pixel-height>549</xocs:pixel-height><xocs:pixel-width>756</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-fx1.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/fx1/DOWNSAMPLED/image/jpeg/4384b1ffd25ec5e7bbd2dca50a99e17e/fx1.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/fx1/DOWNSAMPLED/image/jpeg/4384b1ffd25ec5e7bbd2dca50a99e17e/fx1.jpg</xocs:ucs-locator><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>23255</xocs:filesize><xocs:pixel-height>200</xocs:pixel-height><xocs:pixel-width>217</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr9.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr9/THUMBNAIL/image/gif/7621653f54b4f75d40735bd9e36c558f/gr9.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr9/THUMBNAIL/image/gif/7621653f54b4f75d40735bd9e36c558f/gr9.sml</xocs:ucs-locator><xocs:file-basename>gr9</xocs:file-basename><xocs:filename>gr9.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>14923</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>217</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr8.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr8/THUMBNAIL/image/gif/17a9db7309f41b2e3e16a0af21d51102/gr8.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr8/THUMBNAIL/image/gif/17a9db7309f41b2e3e16a0af21d51102/gr8.sml</xocs:ucs-locator><xocs:file-basename>gr8</xocs:file-basename><xocs:filename>gr8.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>5412</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>187</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr7.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr7/THUMBNAIL/image/gif/98d6157388291b0cf2e38484d3170efb/gr7.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr7/THUMBNAIL/image/gif/98d6157388291b0cf2e38484d3170efb/gr7.sml</xocs:ucs-locator><xocs:file-basename>gr7</xocs:file-basename><xocs:filename>gr7.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>2511</xocs:filesize><xocs:pixel-height>163</xocs:pixel-height><xocs:pixel-width>73</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr6.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr6/THUMBNAIL/image/gif/4735de355d7e42e092418537579bf1c8/gr6.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr6/THUMBNAIL/image/gif/4735de355d7e42e092418537579bf1c8/gr6.sml</xocs:ucs-locator><xocs:file-basename>gr6</xocs:file-basename><xocs:filename>gr6.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>8270</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>135</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr5.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr5/THUMBNAIL/image/gif/17e93daa165e2c3fa884f33cb9b37b88/gr5.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr5/THUMBNAIL/image/gif/17e93daa165e2c3fa884f33cb9b37b88/gr5.sml</xocs:ucs-locator><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>8808</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>131</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr4.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr4/THUMBNAIL/image/gif/938a7c7484abc8e48ef5d29cc2d2b816/gr4.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr4/THUMBNAIL/image/gif/938a7c7484abc8e48ef5d29cc2d2b816/gr4.sml</xocs:ucs-locator><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>4090</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>156</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr3.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr3/THUMBNAIL/image/gif/17b83b584a33eb98fffd4a13cf56a314/gr3.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr3/THUMBNAIL/image/gif/17b83b584a33eb98fffd4a13cf56a314/gr3.sml</xocs:ucs-locator><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>2581</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>52</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr2.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr2/THUMBNAIL/image/gif/a02d65d142dbbb9dc0cacb38ab9b4665/gr2.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr2/THUMBNAIL/image/gif/a02d65d142dbbb9dc0cacb38ab9b4665/gr2.sml</xocs:ucs-locator><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>3202</xocs:filesize><xocs:pixel-height>153</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-gr1.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/gr1/THUMBNAIL/image/gif/df6a7da1319c241fc456d8e5db22b5a6/gr1.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/gr1/THUMBNAIL/image/gif/df6a7da1319c241fc456d8e5db22b5a6/gr1.sml</xocs:ucs-locator><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>5427</xocs:filesize><xocs:pixel-height>159</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913009036-fx1.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913009036/fx1/THUMBNAIL/image/gif/49e0b9acd69ee40ec4843b2a97d308c8/fx1.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913009036/fx1/THUMBNAIL/image/gif/49e0b9acd69ee40ec4843b2a97d308c8/fx1.sml</xocs:ucs-locator><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>6732</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>178</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment></xocs:attachments></xocs:attachment-metadata-doc></xocs:meta><xocs:serial-item><article xmlns="http://www.elsevier.com/xml/ja/dtd" version="5.2" docsubtype="fla" xml:lang="en"><item-info><jid>COREL</jid><aid>6961</aid><ce:pii>S0168-3659(13)00903-6</ce:pii><ce:doi>10.1016/j.jconrel.2013.11.014</ce:doi><ce:copyright type="other" year="2013">The Authors</ce:copyright></item-info><ce:floats><ce:figure id="f0015"><ce:label>Fig. 1</ce:label><ce:caption id="ca0025"><ce:simple-para id="sp0030" view="all">Development of anionic nanoparticles and biophysical characterization. (A) Anionic L<ce:sup loc="post">A</ce:sup>DP nanoparticles were prepared with Method 1 of mixing (L:D:P; liposome with DNA were mixed first followed by mixing with peptide Y) at different molar charge ratios and their size and charge was measured by dynamic light scattering. All formulations had a polydispersity index (PDI) of less than 0.2. (B) Anionic PDL<ce:sup loc="post">A</ce:sup> nanoparticles were prepared with Method 2 of mixing (P:D:L; peptide Y with DNA were mixed first followed by mixing with the liposome) at different molar charge ratios and their size and charge was measured by dynamic light scattering. All formulations had a PDI of less than 0.2. (C) Anionic PEGylated PDL<ce:sup loc="post">AP</ce:sup>1 and PDL<ce:sup loc="post">AP</ce:sup>2 and non-PEGylated PDL<ce:sup loc="post">A</ce:sup> nanoparticles made with Method 2 of mixing were prepared at different molar charge ratios and their size and charge was measured by dynamic light scattering and compared with that of cationic LPD. All formulations had a PDI of less than 0.3. (D) The effect of 50% serum concentration on the relative turbidity of cationic and anionic nanocomplexes over a 30 min incubation period. Cationic LPD nanocomplexes were made at a 1:4:1 weight ratio, whereas the anionic nanocomplexes (non-PEGylated PDL<ce:sup loc="post">A</ce:sup> and PEGylated PDL<ce:sup loc="post">AP</ce:sup>1 and PDL<ce:sup loc="post">AP</ce:sup>2) were all made at a 4:3:1 molar charge ratio. Peptide Y was used for all formulations.</ce:simple-para></ce:caption><ce:link locator="gr1" id="lk0005"/></ce:figure><ce:figure id="f0020"><ce:label>Fig. 2</ce:label><ce:caption id="ca0030"><ce:simple-para id="sp0035" view="all">Heparin dissociation studies to examine packaging properties of the nanocomplexes. The dissociation properties of anionic nanocomplexes PDL<ce:sup loc="post">A</ce:sup>, PDL<ce:sup loc="post">AP</ce:sup>1 and PDL<ce:sup loc="post">AP</ce:sup>2 at 4:3:1 molar charge ratios and cationic nanocomplex LPD were investigated. PicoGreen fluorescence of complexes, after incubation with heparin (0–2<ce:hsp sp="0.25"/>U/mL), was expressed as a percentage of RFU relative to free DNA. Peptide Y was used for all formulations.</ce:simple-para></ce:caption><ce:link locator="gr2" id="lk0010"/></ce:figure><ce:figure id="f0025"><ce:label>Fig. 3</ce:label><ce:caption id="ca0035"><ce:simple-para id="sp0040" view="all">Electron microscopy of nanocomplexes. Negative staining transmission electron microscopy was used to visualize (A) PDL<ce:sup loc="post">A</ce:sup>, (B) PDL<ce:sup loc="post">AP</ce:sup>1 and (C) PDL<ce:sup loc="post">AP</ce:sup>2 nanoparticles. Scale bar<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>100<ce:hsp sp="0.25"/>nm for (A and C) and 500<ce:hsp sp="0.25"/>nm for (B). Peptide Y was used for all formulations.</ce:simple-para></ce:caption><ce:link locator="gr3" id="lk0015"/></ce:figure><ce:figure id="f0030"><ce:label>Fig. 4</ce:label><ce:caption id="ca0040"><ce:simple-para id="sp0045" view="all"><ce:italic>In vitro</ce:italic> transfections with anionic nanocomplexes show the targeting effect of peptide Y and lack of cytotoxicity. (A) Viability of Neuro-2A cells following transfection for 24<ce:hsp sp="0.25"/>h with PDL<ce:sup loc="post">A</ce:sup>, PDL<ce:sup loc="post">AP</ce:sup>1, PDL<ce:sup loc="post">AP</ce:sup>2 and LPD. Cationic nanocomplexes were made at a weight ratio of 1:4:1 (L:P:D) and the anionic nanocomplexes at a molar charge ratio of 4:3:1 (L:P:D). Viability values were normalized to the untransfected control cells. Anionic formulations are shown in gray and cationic formulations in white. Peptide Y was used for all formulations. (B) Nanocomplexes LPD, PDL<ce:sup loc="post">A</ce:sup>, PDL<ce:sup loc="post">AP</ce:sup>1 and PDL<ce:sup loc="post">AP</ce:sup>2 were used in luciferase transfections in Neuro-2A cells, (C) LPD and PDL<ce:sup loc="post">AP</ce:sup>2 in B103 cells and (D) LPD and PDL<ce:sup loc="post">AP</ce:sup>2 in B104 cells. All were made with 3 different peptides: peptide Y, scrambled peptide PS and peptide K<ce:inf loc="post">16</ce:inf>. Cationic nanocomplexes were made at 1:4:1 weight ratio, whereas all anionic were made at 4:3:1 molar charge ratio. (E) Cationic LPD nanocomplexes (weight ratio 1:4:1) and anionic PDL<ce:sup loc="post">AP</ce:sup>2 nanocomplexes at 4:3:1 molar charge ratio and made with three different peptides (peptide Y, scrambled peptide PS and peptide K<ce:inf loc="post">16</ce:inf>) were used in GFP transfections in Neuro-2A cells in serum-containing media. 48<ce:hsp sp="0.25"/>h later the cells were trypsinized and analyzed by flow cytometry for GFP expression. (F) Cationic LPD nanocomplexes (weight ratio 1:4:1) and anionic PDL<ce:sup loc="post">AP</ce:sup>2 nanocomplexes at 4:3:1 molar charge ratio made with two different peptides (peptide Y and scrambled peptide PS) were used in GFP transfections in Neuro-2A cells. Competitive inhibition of peptide Y-mediated gene delivery was performed either in the presence or in the absence of free ligand YL or free scrambled ligand YSL and serum. The cells were pre-incubated with the free ligands at a concentration of 100<ce:hsp sp="0.25"/>μM for 90 min prior to the addition of nanocomplexes. The graph shows %GFP gene expression relative to LPD (Y) for the cationic nanoparticles and relative to PDL<ce:sup loc="post">AP</ce:sup>2 (Y) for the anionic nanoparticles. Each column represents the mean<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>SD from six wells. All transfections were performed in groups of six and mean values were calculated. Asterisks indicate comparisons of specific formulations with statistical significance (*, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05; **, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01; ***, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001).</ce:simple-para></ce:caption><ce:link locator="gr4" id="lk0020"/></ce:figure><ce:figure id="f0035"><ce:label>Fig. 5</ce:label><ce:caption id="ca0045"><ce:simple-para id="sp0050" view="all">GFP transfection efficiency of the PEGylated anionic nanoparticles is higher compared with a cationic counterpart. Two formulations, one cationic (LPD) and one anionic (PDL<ce:sup loc="post">AP</ce:sup>2), were used to transfect Neuro-2A cells in serum-containing media. GFP expression was observed by epifluorescence microscopy 48<ce:hsp sp="0.25"/>h later (representative cells are shown in phase-contrast and transfected cells appear green; 10<ce:hsp sp="0.10"/>× magnification). Peptide Y was used for all formulations. UNTR<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>untransfected cells.</ce:simple-para></ce:caption><ce:link locator="gr5" id="lk0025"/></ce:figure><ce:figure id="f0040"><ce:label>Fig. 6</ce:label><ce:caption id="ca0050"><ce:simple-para id="sp0055" view="all"><ce:italic>In vivo</ce:italic> distribution assessment of charged PEGylated nanoparticles into the striatum and corpus callosum after CED by MRI and histology and reporter gene delivery assessment by qRT-PCR. (A) Optimized 3D T<ce:inf loc="post">1</ce:inf>-weighted gradient echo scans were performed to allow visualization of the gadolinium in the nanoparticles (representative scans from a rat that received Ani PDL<ce:sup loc="post">APRG</ce:sup> nanoparticles), and these data (B) were reconstructed as 3D datasets to allow volumetric distribution analyses after CED in the striatum (red) and corpus callosum (blue) between cationic PEGylated nanoparticles Cat L<ce:sup loc="post">CPRG</ce:sup>PD (left; 1:4:1 weight ratio) and Cat PDL<ce:sup loc="post">APRG</ce:sup> (right; 3:3:1 molar charge ratio) and anionic PEGylated nanoparticles Ani PDL<ce:sup loc="post">APRG</ce:sup> (bottom; 4:3:1 molar charge ratio). (C) Distribution of the anionic and cationic PEGylated nanoparticles following infusions in the striatum and corpus callosum at 48 h post administration was measured. Values are the means of 3 animals<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>standard deviation (*, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05; **, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01; ***, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001). (D) Histological assessment in the striatum of (a–c) cationic PEGylated Cat L<ce:sup loc="post">CPRG</ce:sup>PD nanoparticles, (d–f) Cat PDL<ce:sup loc="post">APRG</ce:sup> nanoparticles, (g–i) anionic Ani PDL<ce:sup loc="post">APRG</ce:sup> nanoparticles. (a, d, g) refer to rhodamine spread, (b, e, h) to GFP expression, (c, f,i ) to the corresponding merged images which show the cellular nature of the striatum by DAPI staining. (E) Cat PDL<ce:sup loc="post">APRG</ce:sup> nanoparticles have shown clear distribution, with several neuronal specific cells detected in the striatum. (a) DAPI stained cells, (b) GFP transfection, (c) NeuN antibody staining and (d) merged panel b and c. Scale bar<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>100<ce:hsp sp="0.25"/>μm; (e) confocal image from the cortex, whereby reflux has allowed visualization of several GFP positive cells following administration of Ani PDL<ce:sup loc="post">APRG</ce:sup> nanoparticles. Scale bar<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>20<ce:hsp sp="0.25"/>μm. (F) Functional delivery of the eGFP plasmid by the cationic (Cat PDL<ce:sup loc="post">AP</ce:sup>2 at 3:3:1 molar charge ratio) and anionic (Ani PDL<ce:sup loc="post">AP</ce:sup>2 at 4:3:1 molar charge ratio) PEGylated nanoparticles was also assessed by qRT-PCR. These two formulations were made without imaging markers. Values represent the mean of the mRNA copies of 3 animals per group<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>standard deviation. Peptide Y was used for all formulations. CC<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>corpus callosum, St<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>striatum.</ce:simple-para></ce:caption><ce:link locator="gr6" id="lk0030"/></ce:figure><ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="t0005" frame="topbot" colsep="0" rowsep="0"><ce:label>Table 1</ce:label><ce:caption id="ca0005"><ce:simple-para id="sp0010" view="all">Composition of liposomes and associated size and zeta potential of nanocomplexes as measured by dynamic light scattering. The molar ratio of each lipid that is used to make the 3 liposomes is shown in parentheses. Cat L<ce:sup loc="post">CPRG</ce:sup>PD was made at 1:4:1 weight ratio, Cat PDL<ce:sup loc="post">APRG</ce:sup> was made at 3:3:1 molar charge ratio and Ani PDL<ce:sup loc="post">APRG</ce:sup> was made at 4:3:1 molar charge ratio. Peptide Y was used for all formulations.</ce:simple-para></ce:caption><tgroup cols="9"><colspec colname="col1"/><colspec colname="col2"/><colspec colname="col3"/><colspec colname="col4"/><colspec colname="col5"/><colspec colname="col6"/><colspec colname="col7"/><colspec colname="col8"/><colspec colname="col9"/><thead><row valign="top" rowsep="1"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">Liposome</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">Lipid 1 (mol %)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">Lipid 2 (mol %)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">Lipid 3 (mol %)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">Lipid 4 (mol %)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">Lipid 5 (mol %)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">LPD/PDL</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">Size (nm)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">ζ potential (mV)</entry></row></thead><tbody><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">L<sup loc="post">CPRG</sup></entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">DOTMA (39.5)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">DOPE (39.5)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">DOPE-PEG2000 (5)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">GdDOTA (GAC<inf loc="post">12</inf>)<inf loc="post">2</inf> (15)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">DOPE-Rhodamine (1)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">Cat L<sup loc="post">CPRG</sup>PD</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">186.0 (± 0.1)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">+<hsp sp="0.10"/>57.0 (±<hsp sp="0.10"/>0.8)</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">L<sup loc="post">APRG</sup></entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">DOPG (39.5)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">DOPE (39.5)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">DOPE-PEG2000 (5)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">GdDOTA (GAC<inf loc="post">12</inf>)<inf loc="post">2</inf> (15)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">DOPE-Rhodamine (1)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">Cat PDL<sup loc="post">APRG</sup></entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">149.8 (±<hsp sp="0.10"/>2.1)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">+<hsp sp="0.10"/>16.9 (±<hsp sp="0.10"/>0.1)</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">L<sup loc="post">APRG</sup></entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">DOPG (39.5)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">DOPE (39.5)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">DOPE-PEG2000 (5)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">GdDOTA (GAC<inf loc="post">12</inf>)<inf loc="post">2</inf> (15)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">DOPE-Rhodamine (1)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">Ani PDL<sup loc="post">APRG</sup></entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">160.5 (±<hsp sp="0.10"/>2.7)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">−<hsp sp="0.10"/>37.9 (±<hsp sp="0.10"/>5.3)</entry></row></tbody></tgroup></ce:table></ce:floats><head><ce:title id="ti0005">PEGylation improves the receptor-mediated transfection efficiency of peptide-targeted, self-assembling, anionic nanocomplexes</ce:title><ce:author-group id="ag0005"><ce:author id="au0005"><ce:given-name>Aristides D.</ce:given-name><ce:surname>Tagalakis</ce:surname><ce:cross-ref refid="af0005" id="cf0005"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="cr0005" id="cf0010"><ce:sup loc="post">⁎</ce:sup></ce:cross-ref><ce:e-address id="em0005" type="email">a.tagalakis@ucl.ac.uk</ce:e-address></ce:author><ce:author id="au0010"><ce:given-name>Gavin D.</ce:given-name><ce:surname>Kenny</ce:surname><ce:cross-ref refid="af0005" id="cf0015"><ce:sup loc="post">a</ce:sup></ce:cross-ref></ce:author><ce:author id="au0015"><ce:given-name>Alison S.</ce:given-name><ce:surname>Bienemann</ce:surname><ce:cross-ref refid="af0010" id="cf0020"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author id="au0020"><ce:given-name>David</ce:given-name><ce:surname>McCarthy</ce:surname><ce:cross-ref refid="af0015" id="cf0025"><ce:sup loc="post">c</ce:sup></ce:cross-ref></ce:author><ce:author id="au0025"><ce:given-name>Mustafa M.</ce:given-name><ce:surname>Munye</ce:surname><ce:cross-ref refid="af0005" id="cf0030"><ce:sup loc="post">a</ce:sup></ce:cross-ref></ce:author><ce:author id="au0030"><ce:given-name>Hannah</ce:given-name><ce:surname>Taylor</ce:surname><ce:cross-ref refid="af0010" id="cf0035"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author id="au0035"><ce:given-name>Marcella J.</ce:given-name><ce:surname>Wyatt</ce:surname><ce:cross-ref refid="af0010" id="cf0040"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author id="au0050"><ce:given-name>Mark F.</ce:given-name><ce:surname>Lythgoe</ce:surname><ce:cross-ref refid="af0020" id="cf0045"><ce:sup loc="post">d</ce:sup></ce:cross-ref></ce:author><ce:author id="au0055"><ce:given-name>Edward A.</ce:given-name><ce:surname>White</ce:surname><ce:cross-ref refid="af0010" id="cf0050"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author id="au0045"><ce:given-name>Stephen L.</ce:given-name><ce:surname>Hart</ce:surname><ce:cross-ref refid="af0005" id="cf0055"><ce:sup loc="post">a</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="af0005"><ce:label>a</ce:label><ce:textfn id="tn0005">Wolfson Centre for Gene Therapy of Childhood Disease, UCL Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK</ce:textfn><sa:affiliation><sa:organization>Wolfson Centre for Gene Therapy of Childhood Disease</sa:organization><sa:organization>UCL Institute of Child Health</sa:organization><sa:organization>University College London</sa:organization><sa:address-line>30 Guilford Street</sa:address-line><sa:city>London</sa:city><sa:postal-code>WC1N 1EH</sa:postal-code><sa:country>UK</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0010"><ce:label>b</ce:label><ce:textfn id="tn0010">Functional Neurosurgery Research Group, School of Clinical Sciences, AMBI Labs, University of Bristol, Southmead Hospital, Bristol BS10 5NB, UK</ce:textfn><sa:affiliation><sa:organization>Functional Neurosurgery Research Group</sa:organization><sa:organization>School of Clinical Sciences</sa:organization><sa:organization>AMBI Labs</sa:organization><sa:organization>University of Bristol</sa:organization><sa:organization>Southmead Hospital</sa:organization><sa:city>Bristol</sa:city><sa:postal-code>BS10 5NB</sa:postal-code><sa:country>UK</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0015"><ce:label>c</ce:label><ce:textfn id="tn0015">UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK</ce:textfn><sa:affiliation><sa:organization>UCL School of Pharmacy</sa:organization><sa:organization>University College London</sa:organization><sa:address-line>29-39 Brunswick Square</sa:address-line><sa:city>London</sa:city><sa:postal-code>WC1N 1AX</sa:postal-code><sa:country>UK</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0020"><ce:label>d</ce:label><ce:textfn id="tn0020">UCL Centre for Advanced Biological Imaging, Division of Medicine and Institute of Child Health, University College London, 72 Huntley Street, London, WC1E 6DD, UK</ce:textfn><sa:affiliation><sa:organization>UCL Centre for Advanced Biological Imaging</sa:organization><sa:organization>Division of Medicine and Institute of Child Health</sa:organization><sa:organization>University College London</sa:organization><sa:address-line>72 Huntley Street</sa:address-line><sa:city>London</sa:city><sa:postal-code>WC1E 6DD</sa:postal-code><sa:country>UK</sa:country></sa:affiliation></ce:affiliation><ce:correspondence id="cr0005"><ce:label>⁎</ce:label><ce:text id="tx0005">Corresponding author: Tel.: +<ce:hsp sp="0.10"/>44 2079052817; fax: +<ce:hsp sp="0.10"/>44 2079052810.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="6" month="10" year="2013"/><ce:date-accepted day="13" month="11" year="2013"/><ce:abstract id="ab0005" view="all" class="author"><ce:section-title id="st0005">Abstract</ce:section-title><ce:abstract-sec id="as0005" view="all"><ce:simple-para id="sp0005" view="all">Non-viral vector formulations comprise typically complexes of nucleic acids with cationic polymers or lipids. However, for <ce:italic>in vivo</ce:italic> applications cationic formulations suffer from problems of poor tissue penetration, non-specific binding to cells, interaction with serum proteins and cell adhesion molecules and can lead to inflammatory responses. Anionic formulations may provide a solution to these problems but they have not been developed to the same extent as cationic formulations due to difficulties of nucleic acid packaging and poor transfection efficiency. We have developed novel PEGylated, anionic nanocomplexes containing cationic targeting peptides that act as a bridge between PEGylated anionic liposomes and plasmid DNA. At optimized ratios, the components self-assemble into anionic nanocomplexes with a high packaging efficiency of plasmid DNA. Anionic PEGylated nanocomplexes were resistant to aggregation in serum and transfected cells with a far higher degree of receptor-targeted specificity than their homologous non-PEGylated anionic and cationic counterparts. Gadolinium-labeled, anionic nanoparticles, administered directly to the brain by convection-enhanced delivery displayed improved tissue penetration and dispersal as well as more widespread cellular transfection than cationic formulations. Anionic PEGylated nanocomplexes have widespread potential for <ce:italic>in vivo</ce:italic> gene therapy due to their targeted transfection efficiency and ability to penetrate tissues.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:abstract class="graphical" id="ab0010" view="all"><ce:section-title id="st1010">Graphical abstract</ce:section-title><ce:abstract-sec id="as0010" view="all"><ce:simple-para id="sp0120" view="all"><ce:display><ce:figure id="f0105"><ce:link locator="fx1" id="lk0135"/></ce:figure></ce:display></ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords id="ks0005" view="all" class="keyword"><ce:section-title id="st0010">Keywords</ce:section-title><ce:keyword id="kw0035"><ce:text id="tx0010">Gene therapy</ce:text></ce:keyword><ce:keyword id="kw0040"><ce:text id="tx0015">Targeted</ce:text></ce:keyword><ce:keyword id="kw0045"><ce:text id="tx0020">Anionic</ce:text></ce:keyword><ce:keyword id="kw0050"><ce:text id="tx0025">Nanoparticle</ce:text></ce:keyword><ce:keyword id="kw0055"><ce:text id="tx0030">MRI</ce:text></ce:keyword><ce:keyword id="kw0060"><ce:text id="tx0035">Self-assembling</ce:text></ce:keyword></ce:keywords></head><body view="all"><ce:sections><ce:section id="s0005" view="all"><ce:label>1</ce:label><ce:section-title id="st0015">Introduction</ce:section-title><ce:para id="p0005" view="all">There is great interest in developing nanocomplex formulations for gene delivery <ce:italic>in vivo</ce:italic> and for therapeutic applications as alternatives to viral vectors, due to their ability to package a wide range of nucleic acids, their low immunogenicity which allows repeated administration and their potential for chemical modification of vector components to optimize performance <ce:cross-refs refid="bb0005 bb0010" id="cf0060">[1,2]</ce:cross-refs>. Non-viral vectors for gene or siRNA delivery usually comprise formulations of cationic polymers or liposomes that self-assemble electrostatically on mixing with nucleic acids at optimized ratios to form cationic nanocomplexes that are often very effective as <ce:italic>in vitro</ce:italic> transfection agents <ce:cross-refs refid="bb0015 bb0020 bb0025 bb0030" id="cf0065">[3–6]</ce:cross-refs> but often display poor transfection efficiency <ce:italic>in vivo</ce:italic> due to their aggregation in serum and to non-specific, charge-mediated binding to anionic cell surfaces and extracellular adhesion molecules <ce:cross-refs refid="bb0035 bb0040 bb0045" id="cf0070">[7–9]</ce:cross-refs>. Stealth coatings, of nanocomplexes, for example by PEGylation, can enhance serum stability and minimize non-specific interactions but usually reduce transfection efficiencies <ce:cross-refs refid="bb0050 bb0055" id="cf0075">[10,11]</ce:cross-refs>.</ce:para><ce:para id="p0010" view="all">An alternative approach is to formulate anionic nanocomplexes that offer the advantages of better targeting specificity, lower cytotoxicity and less interaction with serum components when compared to cationic formulations <ce:cross-refs refid="bb0060 bb0065 bb0070" id="cf0080">[12–14]</ce:cross-refs>. However, the use of anionic nanocomplexes has proven problematic due to the inherent problem of achieving self-assembly with anionic vector components and nucleic acids of the same charge <ce:cross-ref refid="bb0075" id="cf0085">[15]</ce:cross-ref>. Anionic nanocomplexes also display poor transfection efficiency due to charge repulsion at the anionic cell surface and consequently poor cell binding and uptake. Strategies developed to overcome these challenges include using cationic agents such as Ca<ce:sup loc="post">2<ce:hsp sp="0.10"/>+</ce:sup> cations <ce:cross-refs refid="bb0070 bb0080 bb0085 bb0090 bb0095" id="cf0090">[14,16–19]</ce:cross-refs> or protamine <ce:cross-refs refid="bb0100 bb0105 bb0110" id="cf0095">[20–22]</ce:cross-refs> to act as an electrostatic bridge between anionic lipids and nucleic acids, the use of anionic reagents such as polyglutamate to coat cationic nanoparticles with an anionic shell <ce:cross-refs refid="bb0115 bb0120" id="cf0100">[23,24]</ce:cross-refs> or by formulating nanoparticles with pH-tunable lipids <ce:cross-ref refid="bb0125" id="cf0105">[25]</ce:cross-ref>. These anionic formulations and strategies have all shown promise for <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> delivery of DNA and siRNA indicating their potential for non-viral genetic therapies.</ce:para><ce:para id="p0015" view="all">We have previously described a cationic receptor-targeted nanocomplex (RTN), comprising a mixture of cationic liposomes (L), a sixteen lysine peptide with a cyclic seven amino acid targeting domain (P) and plasmid DNA (D) which have achieved efficient <ce:italic>in vivo</ce:italic> gene delivery in the airway epithelium <ce:cross-refs refid="bb0130 bb0135" id="cf0110">[26,27]</ce:cross-refs>, tumors <ce:cross-refs refid="bb0140 bb0145 bb0150" id="cf0115">[28–30]</ce:cross-refs> and vascular tissues <ce:cross-refs refid="bb0155 bb0160" id="cf0120">[31,32]</ce:cross-refs>. Furthermore, we recently have described anionic nanocomplexes that comprised a peptide with a neurotensin receptor-targeting motif and an anionic liposome (1:1 formulation of DOPG:DOPE) which showed targeted transfection <ce:italic>in vitro</ce:italic> and displayed much better distribution in rat brain than homologous cationic nanocomplexes administered by CED <ce:cross-ref refid="bb0165" id="cf0125">[33]</ce:cross-ref>. In this anionic nanocomplex we proposed that the peptide provides a cationic bridge between anionic liposomes and nucleic acids while also providing targeting properties via the receptor-binding peptide ligand.</ce:para><ce:para id="p0020" view="all">The peptide ligand YGLPHKF in peptide Y was identified by biopanning a phage peptide library and closely resembles part of a targeting protein expressed by the intracellular pathogen <ce:italic>Legionella pneumophila</ce:italic> <ce:cross-refs refid="bb0155 bb0170" id="cf0130">[31,34]</ce:cross-refs> although the identity of the receptor is unknown <ce:cross-ref refid="bb0175" id="cf0135">[35]</ce:cross-ref>. However, we have demonstrated that this peptide mediates targeted delivery of siRNA in cationic nanocomplexes to cells of neuronal origin <ce:cross-refs refid="bb0170 bb0180" id="cf0140">[34,36]</ce:cross-refs>. In this study we have adapted this formulation to create anionic nanocomplexes by substituting cationic liposomes with anionic liposomes and adjusting the ratio of peptide and liposome components appropriately. In particular we have explored <ce:italic>in vitro</ce:italic> the effects of PEGylation on the biophysical and transfection properties of the anionic RTNs. <ce:italic>In vivo</ce:italic>, we have compared anionic and cationic PEGylated RTNs for dispersal and transfection in rat brain administered by convection-enhanced delivery (CED), a method that can achieve widespread dispersion of therapeutics from a single administration <ce:cross-refs refid="bb0185 bb0190 bb0195 bb0200 bb0205 bb0210 bb0215" id="cf0145">[37–43]</ce:cross-refs>.</ce:para></ce:section><ce:section id="s0010" view="all"><ce:label>2</ce:label><ce:section-title id="st0020">Materials and methods</ce:section-title><ce:section id="s0015" view="all"><ce:label>2.1</ce:label><ce:section-title id="st0025">Materials</ce:section-title><ce:para id="p0025" view="extended">All lipids used in this study are shown in <ce:cross-ref refid="ec0005" id="cf0150">Supplementary Table 1</ce:cross-ref>. 1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DOPG), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-<ce:italic>sn</ce:italic>-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (DOPE-Rhodamine), 1,2-dipalmitoyl-<ce:italic>sn</ce:italic>-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DPPE-PEG2000), 1,2-dioleoyl-<ce:italic>sn</ce:italic>-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DOPE-PEG2000) and DOTMA/DOPE (1:1 molar ratio) were purchased from Avanti Polar Lipids (Alabaster, Alabama, USA). GdDOTA(GAC<ce:inf loc="post">12</ce:inf>)<ce:inf loc="post">2</ce:inf> was provided by Dr Botta (Alessandria, Italy) <ce:cross-ref refid="bb0220" id="cf0155">[44]</ce:cross-ref>. Peptide Y (K<ce:inf loc="post">16</ce:inf>GACYGLPHKFCG; net charge +<ce:hsp sp="0.10"/>18), ligand YL (YGLPHKF; net charge +<ce:hsp sp="0.10"/>2) and ligand YSL (YKHPGFL; net charge +<ce:hsp sp="0.10"/>2) were synthesized by ChinaPeptides (Shanghai, China), while the non-targeting peptides PS (K<ce:inf loc="post">16</ce:inf>GACHPPMSKLCG; net charge +<ce:hsp sp="0.10"/>18) and peptide K<ce:inf loc="post">16</ce:inf> (KKKKKKKKKKKKKKKK; net charge +<ce:hsp sp="0.10"/>16) were synthesized by Alta Biosciences (Birmingham, UK). The plasmid pCI-Luc consists of the luciferase gene from pGL3 (Invitrogen, Paisley, UK) subcloned into pCI (Promega, Southampton, UK). The plasmid pEGFP-N1 (4.7<ce:hsp sp="0.25"/>kb) containing the gene GFP was obtained from Clontech (Basingstoke, UK). The oligonucleotide primers and standards for qRT-PCR were provided by qStandard (Middlesex, UK) and were as follows: eGFP: forward primer 5′-CTTCAAGATCCGCCACAACAT-3′ and reverse primer 5′-GGTGCTCAGGTAGTGGTTGTC-3′; Rpl13: forward primer 5′-CCCTACAGTTAGATACCACACCAA-3′ and reverse primer 5′-GATACCAGCCACCCTGAGC-3′; Beta actin: forward primer 5′-ACGGTCAGGTCATCACTATCG-3′ and reverse primer 5′-AGCCACCAATCCACACAGA-3′; Sdha: forward primer 5′-TGGACCTTGTCGTCTTTGG-3′ and reverse primer 5′-TTTGCCTTAATCGGAGGAAC-3′.</ce:para><ce:para id="p0027" view="compact-standard">All lipids used in this study are shown in Supplementary Table 1. 1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DOPG), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-<ce:italic>sn</ce:italic>-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (DOPE-Rhodamine), 1,2-dipalmitoyl-<ce:italic>sn</ce:italic>-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DPPE-PEG2000), 1,2-dioleoyl-<ce:italic>sn</ce:italic>-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DOPE-PEG2000) and DOTMA/DOPE (1:1 molar ratio) were purchased from Avanti Polar Lipids (Alabaster, Alabama, USA). GdDOTA(GAC<ce:inf loc="post">12</ce:inf>)<ce:inf loc="post">2</ce:inf> was provided by Dr Botta (Alessandria, Italy) <ce:cross-ref refid="bb0220" id="cf0157">[44]</ce:cross-ref>. Peptide Y (K<ce:inf loc="post">16</ce:inf>GACYGLPHKFCG; net charge +<ce:hsp sp="0.10"/>18), ligand YL (YGLPHKF; net charge +<ce:hsp sp="0.10"/>2) and ligand YSL (YKHPGFL; net charge +<ce:hsp sp="0.10"/>2) were synthesized by ChinaPeptides (Shanghai, China), while the non-targeting peptides PS (K<ce:inf loc="post">16</ce:inf>GACHPPMSKLCG; net charge +<ce:hsp sp="0.10"/>18) and peptide K<ce:inf loc="post">16</ce:inf> (KKKKKKKKKKKKKKKK; net charge +<ce:hsp sp="0.10"/>16) were synthesized by Alta Biosciences (Birmingham, UK). The plasmid pCI-Luc consists of the luciferase gene from pGL3 (Invitrogen, Paisley, UK) subcloned into pCI (Promega, Southampton, UK). The plasmid pEGFP-N1 (4.7<ce:hsp sp="0.25"/>kb) containing the gene GFP was obtained from Clontech (Basingstoke, UK). The oligonucleotide primers and standards for qRT-PCR were provided by qStandard (Middlesex, UK) and were as follows: eGFP: forward primer 5′-CTTCAAGATCCGCCACAACAT-3′ and reverse primer 5′-GGTGCTCAGGTAGTGGTTGTC-3′; Rpl13: forward primer 5′-CCCTACAGTTAGATACCACACCAA-3′ and reverse primer 5′-GATACCAGCCACCCTGAGC-3′; Beta actin: forward primer 5′-ACGGTCAGGTCATCACTATCG-3′ and reverse primer 5′-AGCCACCAATCCACACAGA-3′; Sdha: forward primer 5′-TGGACCTTGTCGTCTTTGG-3′ and reverse primer 5′-TTTGCCTTAATCGGAGGAAC-3′.</ce:para></ce:section><ce:section id="s0020" view="all"><ce:label>2.2</ce:label><ce:section-title id="st0030">Liposome formulation</ce:section-title><ce:para id="p0030" view="all">Lipids were dissolved in chloroform at 10<ce:hsp sp="0.25"/>mg/mL then a lipid film was produced in a rotary evaporator by slowly evaporating the chloroform. Lipids were rehydrated with sterile, distilled water while constantly rotated overnight, and then sonicated in a water bath to reduce their size. Anionic liposomes made were: DOPG:DOPE (L<ce:sup loc="post">A</ce:sup>) at 1:1 molar ratio; DOPG:DOPE:DPPE-PEG2000 (L<ce:sup loc="post">AP</ce:sup>1) at a molar ratio of 47.5:47.5:5<ce:hsp sp="0.25"/>mol%, respectively; DOPG:DOPE:DOPE-PEG2000 (L<ce:sup loc="post">AP</ce:sup>2) at a molar ratio of 47.5:47.5:5<ce:hsp sp="0.25"/>mol%, respectively. An anionic liposome labeled with gadolinium and rhodamine (L<ce:sup loc="post">APRG</ce:sup>) was prepared with a mixture of DOPG:DOPE:DOPE-PEG2000:DOPE-Rhodamine:GdDOTA(GAC<ce:inf loc="post">12</ce:inf>)<ce:inf loc="post">2</ce:inf> at a molar ratio of 39.5:39.5:5:1:15<ce:hsp sp="0.25"/>mol%, respectively. A cationic liposome labeled with gadolinium and rhodamine (L<ce:sup loc="post">CPRG</ce:sup>) was also formulated consisting of DOTMA:DOPE:DOPE-PEG2000:DOPE-Rhodamine:GdDOTA(GAC<ce:inf loc="post">12</ce:inf>)<ce:inf loc="post">2</ce:inf> at a molar ratio of 39.5:39.5:5:1:15<ce:hsp sp="0.25"/>mol%, respectively. A<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>anionic, P<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>PEGylated, C<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>cationic, R<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>rhodamine and G<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>gadolinium.</ce:para></ce:section><ce:section id="s0025" view="all"><ce:label>2.3</ce:label><ce:section-title id="st0035">Nanoparticle formulation</ce:section-title><ce:para id="p0035" view="all">Two methods of formulating anionic nanocomplexes were evaluated. In both, nanocomplexes were prepared in water at a range of molar charge ratios of L to D while the peptide P to D molar charge ratio was maintained constant at 3:1. Method 1 (L:D:P): DNA was first added to an anionic liposome (L<ce:sup loc="post">A</ce:sup>, L<ce:sup loc="post">AP</ce:sup>1 or L<ce:sup loc="post">AP</ce:sup>2) and incubated for 15<ce:hsp sp="0.25"/>min at room temperature and then the peptide was added with rapid mixing and incubated at room temperature for a further 20<ce:hsp sp="0.25"/>min; Method 2 (P:D:L): the peptide was added to the DNA and incubated for 15<ce:hsp sp="0.25"/>min at room temperature and then liposome was added with rapid mixing and incubated at room temperature for a further 20<ce:hsp sp="0.25"/>min. Irrespective of the method of order of mixing, all molar charge ratios in this study refer to L:P:D. Cationic formulations LPD and L<ce:sup loc="post">CPRG</ce:sup>PD were prepared in the order L:P:D as described previously; first, the peptide was added to the liposome DOTMA/DOPE or L<ce:sup loc="post">CPRG</ce:sup> followed by addition of the DNA with rapid mixing and incubated for 30<ce:hsp sp="0.25"/>min at room temperature to allow for complex formation <ce:cross-ref refid="bb0150" id="cf0160">[30]</ce:cross-ref>. The nanocomplexes prepared were termed LPD (liposome DOTMA/DOPE), L<ce:sup loc="post">A</ce:sup>DP and PDL<ce:sup loc="post">A</ce:sup> (liposome L<ce:sup loc="post">A</ce:sup>), PDL<ce:sup loc="post">AP</ce:sup>1 (liposome L<ce:sup loc="post">AP</ce:sup>1), PDL<ce:sup loc="post">AP</ce:sup>2 (liposome L<ce:sup loc="post">AP</ce:sup>2), PDL<ce:sup loc="post">APRG</ce:sup> (liposome L<ce:sup loc="post">APRG</ce:sup>) and L<ce:sup loc="post">CPRG</ce:sup>PD (liposome L<ce:sup loc="post">CPRG</ce:sup>).</ce:para></ce:section><ce:section id="s0030" view="all"><ce:label>2.4</ce:label><ce:section-title id="st0040"><ce:italic>In vitro</ce:italic> transfections</ce:section-title><ce:para id="p0040" view="all">The murine neuroblastoma cell line Neuro-2A (ATCC, Teddington, UK), and the rat neuroblastoma cell lines B104 (ICLC, Genova, Italy) and B103 (AddexBio, San Diego, USA) were maintained in Dulbecco's Modified Eagle Medium, 1% non-essential amino acids, 1<ce:hsp sp="0.25"/>mM sodium pyruvate and 10% FCS (Invitrogen, Paisley, UK). The human bronchial epithelial cells 16HBE14o<ce:hsp sp="0.10"/>− were provided by D. Gruenert (San Francisco, CA, USA) and were cultured in Eagle's Minimal Essential Medium with HEPES modification (Sigma-Aldrich, Poole, UK), 10% FCS and 2<ce:hsp sp="0.25"/>mM<ce:hsp sp="0.25"/><ce:small-caps>l</ce:small-caps>-glutamine. All cells were maintained at 37<ce:hsp sp="0.25"/>°C in a humidified atmosphere in 5% carbon dioxide. Cells were seeded in 96-well plates at 2<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">4</ce:sup> per well 24<ce:hsp sp="0.25"/>h prior to transfection. Following removal of growth medium, 200<ce:hsp sp="0.25"/>μL of the complexes in OptiMEM containing 0.25<ce:hsp sp="0.25"/>μg of plasmid DNA were added to the cells in replicates of six. Plates were centrifuged at 1500<ce:hsp sp="0.25"/>rpm for 5<ce:hsp sp="0.25"/>min (400<ce:hsp sp="0.25"/>×<ce:hsp sp="0.10"/><ce:italic>g</ce:italic>) and incubated for 4<ce:hsp sp="0.25"/>h at 37<ce:hsp sp="0.25"/>°C, then the medium was replaced by the full growth medium and incubated for a further 24<ce:hsp sp="0.25"/>h. Luciferase expression was then measured in cell extracts with a luciferase assay (Promega, Southampton, UK) in a FLUOstar Optima luminometer (BMG Labtech, Aylesbury, UK). The amount of protein present in each cell lysate was determined with the Bio-Rad protein assay reagent (Bio-Rad Laboratories, Hemel Hempstead, UK) in a FLUOstar Optima luminometer. Luciferase activity was expressed as relative light units per milligram of protein (RLU/mg). Each measurement was performed in groups of six and the mean determined.</ce:para><ce:para id="p0045" view="all">Neuro-2A cells were seeded in 96-well plates at 1.2<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">4</ce:sup> per well 24<ce:hsp sp="0.25"/>h prior to transfection with 175<ce:hsp sp="0.25"/>μL complete serum-containing media. Twenty-four hours later, 25<ce:hsp sp="0.25"/>μL of the complexes in OptiMEM containing 0.25<ce:hsp sp="0.25"/>μg of GFP plasmid DNA were added to the cells in replicates of six. Plates were centrifuged at 1500<ce:hsp sp="0.25"/>rpm for 5<ce:hsp sp="0.25"/>min (400<ce:hsp sp="0.25"/>×<ce:hsp sp="0.10"/><ce:italic>g</ce:italic>) and incubated for 48<ce:hsp sp="0.25"/>h at 37<ce:hsp sp="0.25"/>°C. They were then firstly imaged (20<ce:hsp sp="0.10"/>× magnification) using an Olympus IX70 fluorescent microscope (Olympus, Southend-on-Sea, UK) then prepared for flow cytometry by detaching cells from the wells with 50<ce:hsp sp="0.25"/>μL Trypsin-EDTA (Sigma-Aldrich, Poole, UK) and re-suspending them with 150<ce:hsp sp="0.25"/>μL DPBS (Sigma-Aldrich, Poole, UK). Cells were then acquired with a BD FACSArray flow cytometer (BD Biosciences, Oxford, UK) and analyzed with FlowJo software v. 8.8.3 (Tree Star Inc., Ashland, Oregon, USA).</ce:para><ce:para id="p0050" view="all">For competition experiments we modified a previously published method <ce:cross-ref refid="bb0225" id="cf0165">[45]</ce:cross-ref>. Neuro-2A cells were seeded in 96-well plates at 1.2<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">4</ce:sup> per well 24<ce:hsp sp="0.25"/>h prior to transfection. The cells were pre-incubated with free ligands YL or YSL for 90<ce:hsp sp="0.25"/>min prior to the addition of nanocomplexes at a final concentration of 100<ce:hsp sp="0.25"/>μM. The media was then replaced with 200<ce:hsp sp="0.25"/>μL of nanocomplexes per well containing 0.25<ce:hsp sp="0.25"/>μg of GFP plasmid DNA that also contained free ligands YL or YSL at a final concentration of 100<ce:hsp sp="0.25"/>μM. Plates were centrifuged at 1500<ce:hsp sp="0.25"/>rpm for 5<ce:hsp sp="0.25"/>min (400<ce:hsp sp="0.25"/>×<ce:hsp sp="0.10"/><ce:italic>g</ce:italic>) and incubated for 4<ce:hsp sp="0.25"/>h at 37<ce:hsp sp="0.25"/>°C, then the medium was replaced by the full growth medium without any ligands and incubated for a further 48<ce:hsp sp="0.25"/>h. They were then prepared for flow cytometry analysis as above.</ce:para></ce:section><ce:section id="s0035" view="all"><ce:label>2.5</ce:label><ce:section-title id="st0045">Particle size and charge measurements</ce:section-title><ce:para id="p0055" view="all">Nanocomplexes were prepared as above and diluted with distilled water to a final volume of 1<ce:hsp sp="0.25"/>mL and a concentration of 5<ce:hsp sp="0.25"/>μg/mL DNA. They were then analyzed for size and charge (ζ potential) using a Malvern Nano ZS (Malvern, UK). The data were then processed by software provided by the manufacturer, DTS version 5.03. All formulations had a polydispersity index (PDI) of less than 0.3.</ce:para></ce:section><ce:section id="s0040" view="all"><ce:label>2.6</ce:label><ce:section-title id="st0050">Turbidity assay</ce:section-title><ce:para id="p0060" view="all">The turbidity of nanocomplex suspension in different serum concentrations (0–50% v/v) was determined from absorbance at 500<ce:hsp sp="0.25"/>nm on a FLUOstar Optima spectrophotometer with a corresponding amount of serum alone as a reference <ce:cross-ref refid="bb0230" id="cf0170">[46]</ce:cross-ref>. Nanocomplexes were formed as described above with 1<ce:hsp sp="0.25"/>μg DNA in a volume of 200<ce:hsp sp="0.25"/>μL, incubated at 37<ce:hsp sp="0.25"/>°C and analyzed at regular time points over a 30<ce:hsp sp="0.25"/>min period. Relative turbidity was determined by dividing the sample absorbance by the time zero value in water.</ce:para></ce:section><ce:section id="s0045" view="all"><ce:label>2.7</ce:label><ce:section-title id="st0055">PicoGreen fluorescence quenching experiments</ce:section-title><ce:para id="p0065" view="all">Briefly, 0.2<ce:hsp sp="0.25"/>μg DNA was mixed with PicoGreen reagent (1:150) (Invitrogen, Paisley, UK) at room temperature in TE buffer and the DNA/PicoGreen mixture was then formulated into nanocomplexes with anionic liposome and cationic peptide as described above. Fluorescence was analyzed using a fluorescence plate reader, FLUOstar Optima (BMG Labtech, Aylesbury, UK).</ce:para><ce:para id="p0070" view="all">In nanocomplex dissociation assays, heparin sulfate (Sigma-Aldrich, Poole, UK) was added to the PicoGreen-labeled nanocomplexes in a range of concentrations (0.05–2<ce:hsp sp="0.25"/>U/mL). In each experiment, naked DNA stained with PicoGreen was used to normalize the PicoGreen signal detected from the nanocomplexes.</ce:para></ce:section><ce:section id="s0050" view="all"><ce:label>2.8</ce:label><ce:section-title id="st0060">Transmission electron microscopy (TEM)</ce:section-title><ce:para id="p0075" view="all">Prior to use, 300-mesh copper grid coated with a Formvar/carbon support film (Agar Scientific, Essex, UK) were “glow discharged” in an Emitech K350G system (Quorum Technologies, Essex, UK) for 15<ce:hsp sp="0.25"/>s at 30<ce:hsp sp="0.25"/>mA (positive polarity). The anionic nanocomplexes were prepared in water as described above then applied onto a grid and after 5<ce:hsp sp="0.25"/>s dried by blotting with filter paper. The sample was then negatively stained with 1% uranyl acetate for 2–3<ce:hsp sp="0.25"/>s, before blotting with filter paper and air-drying. Imaging was performed with a Philips CM120 BioTwin Transmission Electron Microscope and operated at an accelerating voltage of 120<ce:hsp sp="0.25"/>kV. Images were captured using an AMT 5MP digital TEM camera (Deben UK Limited, Bury St. Edmunds, Suffolk, UK).</ce:para></ce:section><ce:section id="s0055" view="all"><ce:label>2.9</ce:label><ce:section-title id="st0065">Cell proliferation assay</ce:section-title><ce:para id="p0080" view="all">Cell viability was assessed in 96-well plates using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, Southampton, UK). Neuro-2A cells were seeded and transfected with anionic and cationic nanocomplexes as above, then, after 24<ce:hsp sp="0.25"/>h, the media were substituted for growth media containing 20<ce:hsp sp="0.25"/>μL of CellTiter 96 Aqueous One Solution reagent. Finally, after incubation for 2<ce:hsp sp="0.25"/>h, absorbance at 490<ce:hsp sp="0.25"/>nm was measured on a FLUOstar Optima spectrophotometer (BMG Labtech, Aylesbury, UK). Cell viability for each complex was expressed as a percentage of the viability of control cells.</ce:para></ce:section><ce:section id="s0060" view="all"><ce:label>2.10</ce:label><ce:section-title id="st0070"><ce:italic>In vivo</ce:italic> CED procedures</ce:section-title><ce:para id="p0085" view="all">All <ce:italic>in vivo</ce:italic> studies were performed in accordance with the University of Bristol animal care policies and with the authority of appropriate UK Home Office licenses. Adult male Wistar rats (Charles River, Margate, UK, 225 to 275<ce:hsp sp="0.25"/>g) were anesthetized and placed in a small animal stereotaxic frame (Stoelting, Illinois, USA). All CED procedures were performed using a custom-made catheter with an outer diameter of 0.22<ce:hsp sp="0.25"/>mm and inner diameter of 0.15<ce:hsp sp="0.25"/>mm, composed of fused silica with a laser cut tip as described previously <ce:cross-ref refid="bb0215" id="cf0175">[43]</ce:cross-ref>. A total volume of 5<ce:hsp sp="0.25"/>μL of anionic and cationic PEGylated nanoparticles incorporating Gadolinium and Rhodamine (190<ce:hsp sp="0.25"/>ng eGFP/μL) for the striatum and 2.5<ce:hsp sp="0.25"/>μL for the corpus callosum was delivered at an infusion rate of 2.5<ce:hsp sp="0.25"/>μL/min. The Gadolinium dose delivered here is less than 4.5<ce:hsp sp="0.25"/>μg, which is far less than the 50% lethal dose in rodents when the Gadolinium is chelated at 1–2<ce:hsp sp="0.25"/>mg/kg or 100–200<ce:hsp sp="0.25"/>mg/kg for the free ion <ce:cross-ref refid="bb0235" id="cf0180">[47]</ce:cross-ref>. Rats were culled 48<ce:hsp sp="0.25"/>h following CED. For immunohistochemical analysis (IHC), animals were transcardially perfused with 4% paraformaldehyde. Brains were removed and placed in 4% paraformaldehyde for 24<ce:hsp sp="0.25"/>h, then cryoprotected in 30% sucrose in order to be processed for histology. For qRT-PCR, brains were explanted and rapidly frozen at −<ce:hsp sp="0.10"/>80<ce:hsp sp="0.25"/>°C until required.</ce:para></ce:section><ce:section id="s0065" view="all"><ce:label>2.11</ce:label><ce:section-title id="st0075">MRI</ce:section-title><ce:para id="p0090" view="all">MRI measurements were performed on a 9.4<ce:hsp sp="0.25"/>T VNMRS horizontal bore scanner (Varian Inc. Palo Alto, CA) using a 59/26 Rapid quadrature volume coil. Fixed rat brains were imaged using a T<ce:inf loc="post">1</ce:inf>-weighted gradient echo 3D sequence (TR<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>17<ce:hsp sp="0.25"/>ms, TE<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>4<ce:hsp sp="0.25"/>ms, FA<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>52<ce:sup loc="post">o</ce:sup>, 40<ce:hsp sp="0.25"/>μm isotropic resolution, Ave<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>6). Distribution volumes were measured by segmenting the hyperintensities caused by the gadolinium containing nanoparticles using Amira (Visage Imaging Inc., San Diego, CA, USA).</ce:para></ce:section><ce:section id="s0070" view="all"><ce:label>2.12</ce:label><ce:section-title id="st0080">Histological assessment and cell staining</ce:section-title><ce:para id="p0095" view="all">Rat brains were cut into 35<ce:hsp sp="0.25"/>μm thick coronal sections using a Leica CM1850 cryostat (Leica Microsystems, Wetzlar, Germany) at −<ce:hsp sp="0.10"/>20<ce:hsp sp="0.25"/>°C. For fluorescent immunohistochemistry, fixed sections were mounted on gelatine-subbed slides. Once dry, the sections were washed with PBS for 5<ce:hsp sp="0.25"/>min<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>3. Sections were blocked in PBS plus 0.1% triton-x-100 containing 10% normal donkey serum (Sigma-Aldrich, Poole, UK) for 1<ce:hsp sp="0.25"/>h at RT. They were then washed with 0.1% triton-x-100 in PBS for 5<ce:hsp sp="0.25"/>min. Following washing, sections were incubated in the following primary antibodies: mouse anti-NeuN (1:300; Merck Millipore, MA, USA), rabbit anti-GFP (1:200; Merck Millipore, MA, USA). The next day, the primary antibody was removed and sections were washed with 0.1% triton-x-100 in PBS for 5<ce:hsp sp="0.25"/>min<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>3. Sections were incubated with donkey anti-Mouse Cy3 or donkey anti-rabbit Cy3 (1:300; Jackson Laboratories, Sacramento, CA, USA) and DAPI (1:200 of 1<ce:hsp sp="0.25"/>mg/mL; Sigma-Aldrich, Poole, UK) at RT for 2<ce:hsp sp="0.25"/>h in the dark and then washed with PBS for 5<ce:hsp sp="0.25"/>min<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>3. Sections were mounted in Fluorsave™ Reagent (Calbiochem®, Merck Millipore, Billerica, MA, USA) before viewing. Images were captured using the Stereo Investigator platform (MicroBrightField Bioscience, Williston, VT, USA) with a Leica DM5500 microscope (Leica Microsystems, Germany) and digital camera (Microbrightfield Bioscience, Williston, VT, USA). Some slides were visualized by confocal microscopy on a Carl Zeiss LSM710 laser scanning microscope system (Jena, Germany) at a magnification of ×<ce:hsp sp="0.10"/>400.</ce:para></ce:section><ce:section id="s0075" view="all"><ce:label>2.13</ce:label><ce:section-title id="st0085">qRT-PCR</ce:section-title><ce:para id="p0100" view="all">Rat brains (n<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3 per formulation) were collected in RNAlater (Invitrogen, Paisley, UK) and total RNA was extracted from rat brain using the RNeasy kit according to the manufacturer's instructions (Qiagen, Crawley, UK). RNA was checked for integrity using the Agilent 2100 Bioanalyzer (Wokingham, UK). All RNA samples had a RNA integrity number (RIN) of more than 9 indicating high quality RNA. Prior to reverse transcription, each sample underwent DNase treatment (Invitrogen, Paisley, UK) to eliminate any potential genomic DNA contamination. First-strand DNA was synthesized from 1<ce:hsp sp="0.25"/>μg of DNase-treated RNA, using random hexamers and Superscript II reverse transcriptase (Invitrogen, Paisley, UK) in a 1<ce:hsp sp="0.25"/>h reaction at 37<ce:hsp sp="0.25"/>°C. eGFP, rat Succinate dehydrogenase complex subunit A (Sdha), rat Ribosomal protein L13 (Rpl13) and rat beta actin mRNA levels were then quantified by SYBR Green qRT-PCR using a an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Warrington, UK). The qRT-PCR assay conditions were: stage 1, 50<ce:hsp sp="0.25"/>°C for 2<ce:hsp sp="0.25"/>min; stage 2, 95<ce:hsp sp="0.25"/>°C for 10<ce:hsp sp="0.25"/>min; stage 3, 95<ce:hsp sp="0.25"/>°C for 15<ce:hsp sp="0.25"/>s, then 60<ce:hsp sp="0.25"/>°C for 1<ce:hsp sp="0.25"/>min and repeated 40 times. Amplification efficiency was 101% (eGFP), 102% (Rpl13), 102% (beta actin) and 103% (Sdha). Copy numbers for eGFP and the three housekeeping genes were derived from standard curves constructed of purified PCR products generated for each specific primer pair ranging from 10<ce:sup loc="post">7</ce:sup> to 10<ce:sup loc="post">1</ce:sup> copies for eGFP, Rpl13, beta actin and Sdha. Copy numbers of eGFP were normalized against the geometric mean of Rpl13 and beta actin, which were the most stable genes.</ce:para></ce:section><ce:section id="s0080" view="all"><ce:label>2.14</ce:label><ce:section-title id="st0090">Statistical analysis</ce:section-title><ce:para id="p0105" view="all">Data presented in this study are expressed as the mean<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>standard deviation and were analyzed using a two-tailed, unpaired Student <ce:italic>t</ce:italic>-test or one-way ANOVA and Bonferroni post-hoc analysis where applicable. Probability values p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05 were marked with *, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01 were marked with ** and p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001 were marked with ***.</ce:para></ce:section></ce:section><ce:section id="s0085" view="all"><ce:label>3</ce:label><ce:section-title id="st0095">Results</ce:section-title><ce:section id="s0090" view="all"><ce:label>3.1</ce:label><ce:section-title id="st0100">Development and characterization of anionic nanoparticles</ce:section-title><ce:para id="p0110" view="all">LDP (Method 1) or PDL (Method 2) nanocomplexes were formulated at anionic liposome:DNA (L:D) molar charge ratios from 5:1 to 1:1. Zeta potential analysis showed that LDP and PDL nanocomplexes became strongly anionic when the L:D molar charge ratio was 3.5:1 or greater with no significant size or charge differences (<ce:cross-ref refid="f0015" id="cf0185">Fig. 1</ce:cross-ref>A and B<ce:float-anchor refid="f0015"/>).</ce:para><ce:para id="p0115" view="extended">PicoGreen fluorescence assays (<ce:cross-ref refid="f0005" id="cf0190">Fig. 1S</ce:cross-ref>-A) showed that PDL formulations quenched fluorescence better than LDP formulations at the 5:3:1 molar charge ratio (37% quenching for LDP vs. 61% for PDL; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01) but there was no difference at the 4:3:1 ratio. Luciferase transfection efficiency comparisons in B104 and 16HBE14o<ce:hsp sp="0.10"/>− cells (<ce:cross-ref refid="f0005" id="cf0195">Fig. 1S</ce:cross-ref>-B and C, respectively) showed that the PDL order of mixing was substantially better than LDP at all molar charge ratios. Therefore, based on packaging and transfection efficiencies, the PDL method of mixing was used thereafter for all anionic nanocomplexes.</ce:para><ce:para id="p0117" view="compact-standard">PicoGreen fluorescence assays (Fig. 1S-A) showed that PDL formulations quenched fluorescence better than LDP formulations at the 5:3:1 molar charge ratio (37% quenching for LDP vs. 61% for PDL; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01) but there was no difference at the 4:3:1 ratio. Luciferase transfection efficiency comparisons in B104 and 16HBE14o<ce:hsp sp="0.10"/>− cells (Fig. 1S-B and C, respectively) showed that the PDL order of mixing was substantially better than LDP at all molar charge ratios. Therefore, based on packaging and transfection efficiencies, the PDL method of mixing was used thereafter for all anionic nanocomplexes.</ce:para><ce:para id="p0120" view="all">Anionic liposomes (DOPG/DOPE) were then prepared with PEGylated lipids incorporated at 5% molar ratios and these liposomes were used to prepare the anionic PEGylated nanocomplexes PDL<ce:sup loc="post">AP</ce:sup>1, containing the DPPE-PEG2000 liposome, and PDL<ce:sup loc="post">AP</ce:sup>2 containing DOPE-PEG2000. The PEGylated nanocomplexes were both prepared at molar charge ratios of 5:3:1 and 4:3:1 and were confirmed to be anionic (<ce:cross-ref refid="f0015" id="cf0200">Fig. 1</ce:cross-ref>C). PDL<ce:sup loc="post">AP</ce:sup>2 nanocomplexes were bigger than both the non-PEGylated PDL<ce:sup loc="post">A</ce:sup> and cationic LPD (<ce:cross-ref refid="f0015" id="cf0205">Fig. 1</ce:cross-ref>C) while they were also less anionic (e.g. −<ce:hsp sp="0.10"/>36<ce:hsp sp="0.25"/>mV for PDL<ce:sup loc="post">AP</ce:sup>2 compared to −<ce:hsp sp="0.10"/>49<ce:hsp sp="0.25"/>mV for PDL<ce:sup loc="post">A</ce:sup>). The stability of nanocomplexes in 50% mouse serum was assessed where the turbidity of both PEGylated and non-PEGylated, anionic PDL nanocomplexes was less than half that of the cationic LPD formulation (<ce:cross-ref refid="f0015" id="cf0210">Fig. 1</ce:cross-ref>D).</ce:para><ce:para id="p0125" view="all">The ability of anionic nanocomplexes to package DNA efficiently and to dissociate following heparin challenge in order to release intact DNA was then assessed. PicoGreen-labeled DNA was formulated into cationic LPD and anionic PDL, PEGylated and non-PEGylated nanocomplexes at 4:3:1 molar charge ratios. Packaging was inferred from quenching of fluorescence compared to free DNA as 100%. Non-PEGylated PDL<ce:sup loc="post">A</ce:sup> at 65% quenching, packaged less well than cationic LPD at 85% quenching, although PEGylation improved packaging in anionic formulations with both PDL<ce:sup loc="post">AP</ce:sup>1 and PDL<ce:sup loc="post">AP</ce:sup>2 also quenching DNA fluorescence by 80% (<ce:cross-ref refid="f0020" id="cf0215">Fig. 2</ce:cross-ref><ce:float-anchor refid="f0020"/>). On the other hand, PDL<ce:sup loc="post">A</ce:sup> was the least sensitive formulation to heparin with fluorescence increasing only to 48.8%, even in the presence of 2<ce:hsp sp="0.25"/>U/mL heparin, whereas cationic LPD only required 0.4<ce:hsp sp="0.25"/>U/mL heparin to achieve 50% dissociation. PEGylation of anionic nanocomplexes greatly increased their sensitivity to heparin, achieving 50% dissociation at 0.14<ce:hsp sp="0.25"/>U/mL heparin for PDL<ce:sup loc="post">AP</ce:sup>1 and 0.32<ce:hsp sp="0.25"/>U/mL of heparin for PDL<ce:sup loc="post">AP</ce:sup>2 nanocomplexes (<ce:cross-ref refid="f0020" id="cf0220">Fig. 2</ce:cross-ref>).</ce:para><ce:para id="p0130" view="all">Anionic PDL nanoparticle formulations were further characterized by negative staining transmission electron microscopy (TEM) to determine shape and morphology. Most nanocomplexes were spheres but with some rods, while PDL<ce:sup loc="post">AP</ce:sup>2 also showed some ‘doughnut’ structures (<ce:cross-ref refid="f0025" id="cf0225">Fig. 3</ce:cross-ref><ce:float-anchor refid="f0025"/>). The majority of the spherical particles for each formulation were in the range determined by particle size analysis with no obvious differences between formulations.</ce:para></ce:section><ce:section id="s0095" view="all"><ce:label>3.2</ce:label><ce:section-title id="st0105">Enhanced targeted cell transfection efficiency and viability of anionic PDLs</ce:section-title><ce:para id="p0135" view="all">Anionic PDL formulations were then compared with cationic formulations for cytotoxicity and targeted transfection efficiency in three neuroblastoma cell lines, mouse Neuro-2a and rat B103 and B104. In MTS toxicity assays of transfected Neuro-2A cells (<ce:cross-ref refid="f0030" id="cf0230">Fig. 4</ce:cross-ref>A<ce:float-anchor refid="f0030"/>) all three anionic formulations were less toxic than cationic LPD (p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01). In Neuro-2A cells (<ce:cross-ref refid="f0030" id="cf0235">Fig. 4</ce:cross-ref>B), both PEGylated anionic nanocomplexes were more efficient transfection agents than the non-PEGylated PDL<ce:sup loc="post">A</ce:sup> (p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001) with PDL<ce:sup loc="post">AP</ce:sup>2 showing optimal transfection efficiency and receptor specificity. The targeted transfection efficiency of anionic nanocomplexes with the targeting peptide, peptide Y, was 17.6-fold, 80.3-fold and 75-fold higher than those with K<ce:inf loc="post">16</ce:inf> and 5-fold, 2.6-fold and 11.7-fold higher than those with peptide PS for PDL<ce:sup loc="post">A</ce:sup>, PDL<ce:sup loc="post">AP</ce:sup>1 and PDL<ce:sup loc="post">AP</ce:sup>2, respectively, while cationic LPD formulations with peptide Y were enhanced only 1.8-fold compared to K<ce:inf loc="post">16</ce:inf> and 1.3-fold compared to PS, highlighting the greater targeting specificity of the anionic formulations. The transfection efficiency of PDL<ce:sup loc="post">AP</ce:sup>2 containing peptide Y was significantly better than PDL<ce:sup loc="post">AP</ce:sup>1 (p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01) and this was also the more stable formulation in the heparin dissociation studies.</ce:para><ce:para id="p0140" view="all">The same trends were observed in B103 cells (<ce:cross-ref refid="f0030" id="cf0240">Fig. 4</ce:cross-ref>C) and B104 cells (<ce:cross-ref refid="f0030" id="cf0245">Fig. 4</ce:cross-ref>D) where the targeted transfection efficiency and specificity of anionic PDL<ce:sup loc="post">AP</ce:sup>2 was again significantly better than that of cationic LPD (p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001). PDL<ce:sup loc="post">AP</ce:sup>2 with peptide Y was about two-fold better than the scrambled PS formulation (p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05) although both anionic and cationic formulations were significantly improved over non-targeting K<ce:inf loc="post">16</ce:inf> formulations. In B104 cells (<ce:cross-ref refid="f0030" id="cf0250">Fig. 4</ce:cross-ref>D) the transfection efficiency of peptide Y-targeted PDL<ce:sup loc="post">AP</ce:sup>2 formulation was more than thirty-fold better than that that of the scrambled PS and non-targeting K<ce:inf loc="post">16</ce:inf> formulations and almost 2-fold better than the peptide Y-targeted cationic LPD formulation.</ce:para><ce:para id="p4025" view="extended">The transfection efficiencies of anionic PEGylated formulations were then compared with the plasmid expressing enhanced green fluorescent protein (GFP) in Neuro-2A cells. Flow cytometry analysis showed that, in the presence of 10% serum, peptide Y-targeted PDL<ce:sup loc="post">AP</ce:sup>2 transfected up to 65% of cells while Y-targeted cationic LPD formulations transfected a maximum of 22% cells (p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001; <ce:cross-ref refid="f0030" id="cf9955">Fig. 4</ce:cross-ref>E). In addition, targeted transfection specificity was again more evident with PDL<ce:sup loc="post">AP</ce:sup>2 than LPD when comparing with K<ce:inf loc="post">16</ce:inf> and PS-containing formulations (<ce:cross-ref refid="f0030" id="cf4460">Fig. 4</ce:cross-ref>E). The specificity of gene delivery by peptide Y was further demonstrated in competition experiments using excess free ligand YL (i.e. only the targeting motif of peptide Y) or excess free scrambled ligand YSL (i.e. only a scrambled motif). GFP transfection following peptide Y-mediated gene delivery was 44-fold and 8-fold reduced (p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001 for both) when the gene transfer was performed in the presence of free ligand YL for PDL<ce:sup loc="post">AP</ce:sup>2 and LPD nanocomplexes, respectively, whereas no significant difference was observed in the presence of free ligand YSL (<ce:cross-ref refid="f0030" id="cf9965">Fig. 4</ce:cross-ref>F). There was no effect of ligand YL or ligand YSL on peptide PS-mediated gene transfer. Reduction in reporter gene transfection was also observed when the competition experiments were performed for luciferase expression in the presence of YL ligand (approximately 12-fold and 4-fold for PDL<ce:sup loc="post">AP</ce:sup>2 and LPD, respectively; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001 for both), whereas no effect was observed in the presence of YSL (Fig. 2S). Fluorescent microscopy images also provided evidence of the high transfection efficiency of PDL<ce:sup loc="post">AP</ce:sup>2 anionic nanoparticles (<ce:cross-ref refid="f0035" id="cf9895">Fig. 5</ce:cross-ref>).</ce:para><ce:para id="p3027" view="compact-standard">The transfection efficiencies of anionic PEGylated formulations were then compared with the plasmid expressing enhanced green fluorescent protein (GFP) in Neuro-2A cells. Flow cytometry analysis showed that, in the presence of 10% serum, peptide Y-targeted PDL<ce:sup loc="post">AP</ce:sup>2 transfected up to 65% of cells while Y-targeted cationic LPD formulations transfected a maximum of 22% cells (p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001; <ce:cross-ref refid="f0030" id="cf0255">Fig. 4</ce:cross-ref>E). In addition, targeted transfection specificity was again more evident with PDL<ce:sup loc="post">AP</ce:sup>2 than LPD when comparing with K<ce:inf loc="post">16</ce:inf> and PS-containing formulations (<ce:cross-ref refid="f0030" id="cf0260">Fig. 4</ce:cross-ref>E). The specificity of gene delivery by peptide Y was further demonstrated in competition experiments using excess free ligand YL (i.e. only the targeting motif of peptide Y) or excess free scrambled ligand YSL (i.e. only a scrambled motif). GFP transfection following peptide Y-mediated gene delivery was 44-fold and 8-fold reduced (p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001 for both) when the gene transfer was performed in the presence of free ligand YL for PDL<ce:sup loc="post">AP</ce:sup>2 and LPD nanocomplexes, respectively, whereas no significant difference was observed in the presence of free ligand YSL (<ce:cross-ref refid="f0030" id="cf0265">Fig. 4</ce:cross-ref>F). There was no effect of ligand YL or ligand YSL on peptide PS-mediated gene transfer. Reduction in reporter gene transfection was also observed when the competition experiments were performed for luciferase expression in the presence of YL ligand (approximately 12-fold and 4-fold for PDL<ce:sup loc="post">AP</ce:sup>2 and LPD, respectively; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001 for both), whereas no effect was observed in the presence of YSL (Fig. 2S). Fluorescent microscopy images also provided evidence of the high transfection efficiency of PDL<ce:sup loc="post">AP</ce:sup>2 anionic nanoparticles (<ce:cross-ref refid="f0035" id="cf8265">Fig. 5</ce:cross-ref><ce:float-anchor refid="f0035"/>).</ce:para></ce:section><ce:section id="s0100" view="all"><ce:label>3.3</ce:label><ce:section-title id="st0110"><ce:italic>In vivo</ce:italic> administration by CED of anionic PDLs demonstrated significant brain distribution and transgene expression</ce:section-title><ce:para id="p0150" view="all">Targeted, anionic and cationic, PEGylated formulations were prepared with liposomes labeled with fluorescent rhodamine and gadolinium, an MRI contrast agent (<ce:cross-ref refid="t0005" id="cf0275">Table 1</ce:cross-ref><ce:float-anchor refid="t0005"/>). Formulations containing GFP were administered to rat brains by CED into the corpus callosum and the striatum then analyzed at 48<ce:hsp sp="0.25"/>h for distribution by MRI. Analysis by MRI (<ce:cross-ref refid="f0040" id="cf0280">Fig. 6</ce:cross-ref>A<ce:float-anchor refid="f0040"/>) and 3D reconstructions (<ce:cross-ref refid="f0040" id="cf0285">Fig. 6</ce:cross-ref>B) showed that in the corpus callosum infusions the distribution volumes of anionic Ani PDL<ce:sup loc="post">APRG</ce:sup> formulations was increased approximately 2-fold (p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05) and 22-fold (p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001) compared to the cationic formulations Cat PDL<ce:sup loc="post">APRG</ce:sup> and Cat L<ce:sup loc="post">CPRG</ce:sup>PD, respectively (<ce:cross-ref refid="f0040" id="cf0290">Fig. 6</ce:cross-ref>C). Distribution volumes for all formulations were lower in the striatum than the corpus callosum due to the denser nature of the tissue but an increase in distribution of anionic Ani PDL<ce:sup loc="post">APRG</ce:sup> nanocomplexes compared to Cat PDL<ce:sup loc="post">APRG</ce:sup> (5-fold; p<ce:hsp sp="0.25"/>&gt;<ce:hsp sp="0.25"/>0.05) and Cat L<ce:sup loc="post">CPRG</ce:sup>PD formulations (25-fold; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01) was observed in the striatum infusions.</ce:para><ce:para id="p0155" view="extended">Histological analysis of brain sections (<ce:cross-ref refid="f0040" id="cf0295">Figs. 6</ce:cross-ref>D and <ce:cross-ref refid="f0010" id="cf0300">3S</ce:cross-ref>) also suggested better distribution of the anionic rather than cationic nanoparticles but was not quantified. Rat brain sections (<ce:cross-ref refid="f0040" id="cf0305">Fig. 6</ce:cross-ref>E) showed that the rhodamine-labeled nanoparticles expressed GFP within the striatum as well as the cortex, where transfection occurred due to nanoparticles refluxed up the catheter tract on withdrawal of the cannula. Confirmation of GFP transgene expression was achieved by quantitative real time polymerase chain reaction (qRT-PCR) using samples of total RNA (<ce:cross-ref refid="f0040" id="cf0310">Fig. 6</ce:cross-ref>F) from two regions of the brain (corpus callosum and striatum). Highest expression levels were achieved by cationic formulation Cat PDL<ce:sup loc="post">AP</ce:sup>2 especially in the striatum, followed by the anionic formulation Ani PDL<ce:sup loc="post">AP</ce:sup>2, with no statistical differences among the groups.</ce:para><ce:para id="p0157" view="compact-standard">Histological analysis of brain sections (<ce:cross-ref refid="f0040" id="cf0297">Figs. 6</ce:cross-ref>D and 3S) also suggested better distribution of the anionic rather than cationic nanoparticles but was not quantified. Rat brain sections (<ce:cross-ref refid="f0040" id="cf0307">Fig. 6</ce:cross-ref>E) showed that the rhodamine-labeled nanoparticles expressed GFP within the striatum as well as the cortex, where transfection occurred due to nanoparticles refluxed up the catheter tract on withdrawal of the cannula. Confirmation of GFP transgene expression was achieved by quantitative real time polymerase chain reaction (qRT-PCR) using samples of total RNA (<ce:cross-ref refid="f0040" id="cf0312">Fig. 6</ce:cross-ref>F) from two regions of the brain (corpus callosum and striatum). Highest expression levels were achieved by cationic formulation Cat PDL<ce:sup loc="post">AP</ce:sup>2 especially in the striatum, followed by the anionic formulation Ani PDL<ce:sup loc="post">AP</ce:sup>2, with no statistical differences among the groups.</ce:para></ce:section></ce:section><ce:section id="s0105" view="all"><ce:label>4</ce:label><ce:section-title id="st0115">Discussion</ce:section-title><ce:para id="p0160" view="all">Many of the limitations of synthetic nanoparticle formulations <ce:italic>in vivo</ce:italic>, such as poor tissue specificity, toxicity and rapid clearance from the circulation, relate to their cationic surface charges. Stealth coatings such as PEGylation overcome some of these problems but often lead to reduced transfection efficiency <ce:cross-ref refid="bb0055" id="cf0315">[11]</ce:cross-ref>. For these reasons, neutral and anionic nanocomplex formulations have gained traction in the field in recent years although the level of research remains far below that of cationic formulations. One of the first such approaches involved a formulation of anionic liposomes and cationic protamine with DNA, targeted to tumor cells by folate <ce:cross-ref refid="bb0240" id="cf0320">[48]</ce:cross-ref> and various derivatives of this formulation have been developed in recent years <ce:cross-refs refid="bb0105 bb0110 bb0245 bb0250 bb0255" id="cf0325">[21,22,49–51]</ce:cross-refs>. Other effective approaches of preparing anionic nanocomplexes involve the use of electrostatic, anionic coating agents such as hyaluronan, polyglutamate and chondroitin sulfate applied to a cationic core nanoparticle <ce:cross-refs refid="bb0260 bb0265 bb0270 bb0275" id="cf0330">[52–55]</ce:cross-refs>. Such approaches have enabled the production of highly anionic nanoparticles that display comparable levels of transfection to cationic formulations but with advantages of greater specificity and lower cytotoxicity. Anionic DNA-delivery formulations have shown promising evidence of improved efficacy, biodistribution and reduced toxicity compared to cationic formulations when administered systemically for targeting of tumors <ce:cross-refs refid="bb0115 bb0240 bb0265 bb0280" id="cf0335">[23,48,53,56]</ce:cross-refs>. Anionic formulations have also been described for siRNA transfection with similarly promising results <ce:cross-refs refid="bb0080 bb0085 bb0120 bb0285 bb0290" id="cf0340">[16,17,24,57,58]</ce:cross-refs>. There is therefore a need for more research into the potential of anionic formulations to optimize their design, formulation and applications.</ce:para><ce:para id="p0165" view="all">We are developing a platform of anionic, targeted nanocomplex formulations comprising a mixture of peptide ligands and anionic liposomes that self-assemble into anionic nanocomplexes with DNA at optimized ratios of components and order of mixing. Our first such formulation displayed far superior distribution in rat brain than homologous cationic nanocomplexes following CED administration <ce:cross-ref refid="bb0165" id="cf0345">[33]</ce:cross-ref>. Here we have focused on developing this formulation further, investigating the effects of PEGylation and an alternative targeting moiety, peptide Y. We relate the biophysical properties of these novel nanocomplexes to their transfection efficiencies <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> in rat brain, as well as brain distribution by MRI.</ce:para><ce:para id="p0170" view="all">Anionic nanocomplex formulation protocols were first optimized in terms of method of mixing and molar charge ratios, then structural and functional studies were performed to compare the PEGylated formulations with non-PEGylated anionic and cationic formulations. The cationic LPD nanoparticles had a similar size to the anionic non-PEGylated PDL<ce:sup loc="post">A</ce:sup>. The anionic PEGylated nanoparticles were slightly larger in diameter than non-PEGylated anionic formulations, while their charge was less anionic due probably to PEG shielding. TEM images of anionic nanoparticles showed that there were no significant differences in morphology between the different PEGylated and non-PEGylated anionic formulations and cationic LPD formulations reported previously <ce:cross-ref refid="bb0170" id="cf0350">[34]</ce:cross-ref>.</ce:para><ce:para id="p0175" view="all">DNA packaging was significantly less efficient in anionic PDL<ce:sup loc="post">A</ce:sup> formulations than in cationic LPD although PEGylation improved it to 80% from 65% in the non-PEGylated anionic formulation, which matched that of the cationic LPD formulation with approximately 85% efficiency. We then tested nanoparticle stability using mouse serum at 50% concentration (v/v) which approximates <ce:italic>in vivo</ce:italic> conditions <ce:cross-ref refid="bb0230" id="cf0355">[46]</ce:cross-ref>. PEGylated and non-PEGylated PDL<ce:sup loc="post">A</ce:sup> formulations were far more stable in serum than cationic nanocomplexes which aggregated due to their interactions with anionic serum proteins <ce:cross-ref refid="bb0295" id="cf0360">[59]</ce:cross-ref>. Aggregation of cationic liposomes leads to reduced bioavailability, increased toxicity, reduced binding to cells and clearance <ce:italic>in vivo</ce:italic> of cationic nanoparticles by the reticuloendothelial system (RES) <ce:cross-refs refid="bb0230 bb0300" id="cf0365">[46,60]</ce:cross-refs> and so we anticipate improved properties for anionic nanoparticles administered systemically.</ce:para><ce:para id="p0180" view="all">While extracellular stability is an essential requirement for an efficient nucleic acid delivery formulation, effective transfection is also influenced by the ease of release of the cargo within the cell <ce:cross-ref refid="bb0180" id="cf0370">[36]</ce:cross-ref>. The cationic LPD formulation dissociated more easily and to a greater extent after treatment with heparin than PDL<ce:sup loc="post">A</ce:sup>. However, PEGylation greatly enhanced the dissociation potential of anionic nanocomplexes particularly for PDL<ce:sup loc="post">AP</ce:sup>1. The PEGylated lipid moiety in PDL<ce:sup loc="post">AP</ce:sup>1 is a C16 saturated acyl chain while in PDL<ce:sup loc="post">AP</ce:sup>2 it is a C18 unsaturated acyl chain. Longer acyl chains (C18 vs. C16) strengthen membrane cohesion of liposomes and this may explain the greater stability of PDL<ce:sup loc="post">AP</ce:sup>2 <ce:cross-ref refid="bb0305" id="cf0375">[61]</ce:cross-ref>. In addition, PEG-lipids with the shortest acyl chain, provided the least liposome protection with rapid elimination of the liposomes from the circulation within 1<ce:hsp sp="0.25"/>h after liposome injection <ce:cross-ref refid="bb0310" id="cf0380">[62]</ce:cross-ref>. The different sensitivities of PEGylated and non-PEGylated anionic nanocomplexes to heparin, may be explained by the greater anionic charge of the latter increasing resistance to dissociation. Toxicity assays showed that there was no difference between the PEGylated and non-PEGylated anionic formulations although there was some evidence of toxicity for the cationic formulations consistent with previous studies comparing anionic and cationic formulations <ce:cross-refs refid="bb0105 bb0110 bb0120" id="cf0385">[21,22,24]</ce:cross-refs>.</ce:para><ce:para id="p0185" view="all">We then compared the transfection efficiencies of the anionic formulations in different cell lines using different peptides, targeting (peptide Y) and non-targeting (peptides PS and K<ce:inf loc="post">16</ce:inf>). Comparing peptide Y-targeted nanocomplexes, PDL<ce:sup loc="post">AP</ce:sup>2 formulations produced significantly better luciferase transfection efficiencies than PDL<ce:sup loc="post">AP</ce:sup>1 and similar to the efficiency of a cationic LPD formulation, while non-PEGylated PDL<ce:sup loc="post">A</ce:sup> was far less efficient. GFP transfections also showed the greater transfection efficiency of PDL<ce:sup loc="post">AP</ce:sup>2 when compared to PDL<ce:sup loc="post">AP</ce:sup>1 and cationic LPD formulations.</ce:para><ce:para id="p0190" view="all">Peptide Y-targeted anionic formulations produced much better transfection efficiencies than their non-targeted counterparts containing peptide PS or K<ce:inf loc="post">16</ce:inf> in all cell lines examined, suggesting receptor-specific transfection. The receptor for peptide Y is unknown and so to evaluate receptor-mediated transfection specificity, cells were incubated with the competing peptide ligand, YL, before transfecting with peptide Y-containing nanocomplexes. This led to reduced transfection of both peptide Y-targeted anionic and cationic nanocomplexes, although the degree of inhibition of transfection was much greater with the anionic formulation. The scrambled control peptide, YSL, had no effect on transfection in targeted formulations, while transfections of cells containing non-targeting peptide PS were not affected by either YL or YSL. These studies support the hypothesis that anionic nanocomplexes transfect by receptor-specific pathways, while cationics transfect by charge-mediated non-specific routes, which can be enhanced by a targeting peptide ligand.</ce:para><ce:para id="p0195" view="all">In relating differences in transfection efficiency to biophysical properties, PDL<ce:sup loc="post">A</ce:sup>, the least effective transfection agent, possessed the highest anionic charge and was the least efficient formulation for both DNA packaging and release, although its high anionic charge was associated with significantly higher specificity for ligand-mediated transfection than that of cationic LPD. The high anionic surface charge would reduce cell surface interactions and endocytosis and this, combined with the poor DNA release kinetics help to explain the poor transfection efficiency compared to the cationic LPD. The improved transfection efficiency of PEGylated anionic formulations was associated with improved dynamic properties of the nanocomplexes in that they both packaged and released DNA more effectively than the non-PEGylated formulation and had lower anionic surface charge. In fact the optimal PEGylated formulation PDL<ce:sup loc="post">AP</ce:sup>2 was a better transfection agent than even the cationic LPD, displaying a much higher degree of receptor-mediated transfection than cationic formulations. Of the two PEGylated formulations PDL<ce:sup loc="post">AP</ce:sup>2 was slightly more stable to heparin-mediated dissociation than PDL<ce:sup loc="post">AP</ce:sup>1 but otherwise presented with similar biophysical properties of size, charge and morphology. Thus PDL<ce:sup loc="post">AP</ce:sup>2 may better retain its structural integrity during the transfection process in the anionic environment of the cell surface while retaining greater dynamic properties for DNA release within the cell, and hence achieve the greater transfection efficiencies observed.</ce:para><ce:para id="p0200" view="all">We then investigated an <ce:italic>in vivo</ce:italic> application involving direct injection of nanoparticles to the brain by CED where anionic formulations offer the promise, of more widespread dispersal of nanoparticles from a single administration as they are less likely to adhere to cells non-specifically than similarly sized cationic nanoparticles <ce:cross-refs refid="bb0165 bb0215" id="cf0390">[33,43]</ce:cross-refs>, while other studies suggested that surface modification by PEGylation further enhanced distribution of anionic <ce:cross-ref refid="bb0315" id="cf0395">[63]</ce:cross-ref> but not of cationic nanoparticles <ce:cross-refs refid="bb0280 bb0315" id="cf0400">[56,63]</ce:cross-refs>. In this study, nanocomplex formulations were labeled with gadolinium and rhodamine to enable detection by MRI and fluorescence microscopy, respectively <ce:cross-ref refid="bb0165" id="cf0420">[33]</ce:cross-ref>. Formulations compared for dispersal within the brain and transfection included, i) an anionic PDL<ce:sup loc="post">AP</ce:sup>2-based formulation, Ani PDL<ce:sup loc="post">APRG</ce:sup>, ii) a cationic formulation, Cat PDL<ce:sup loc="post">APRG</ce:sup>, containing the same anionic liposome as PDL<ce:sup loc="post">AP</ce:sup>2 but formulated with a lower amount of the anionic liposome (DOPG/DOPE) to make cationic nanocomplexes, and iii) a second cationic nanocomplex, Cat L<ce:sup loc="post">CPRG</ce:sup>PD, prepared with cationic liposomes. The distribution of the anionic formulation by MRI was greater than either cationic formulation in both striatum and corpus callosum. The difference in distribution between the Cat L<ce:sup loc="post">CPRG</ce:sup>PD and Cat PDL<ce:sup loc="post">APRG</ce:sup>, may be attributed to the higher positive charge (+<ce:hsp sp="0.10"/>57.0 and +<ce:hsp sp="0.10"/>16.9<ce:hsp sp="0.25"/>mV, respectively) (<ce:cross-ref refid="t0005" id="cf0425">Table 1</ce:cross-ref>) leading to an increase in non-specific binding close to the cannula tip <ce:cross-ref refid="bb0315" id="cf0430">[63]</ce:cross-ref>. Distribution for all formulations was greater in the corpus callosum infusions due to the more compact nature of the striatum and the consequent importance of size limitations on distribution. The qRT-PCR analysis confirmed that GFP transgene expression was achieved in two regions of the brain (corpus callosum and striatum). All formulations achieved transgene expression in both brain areas with no statistical differences among the different groups. The higher local concentration of the cationic formulation may provide an advantage for transfection near the injection site compared to the anionic formulations, which are better dispersed but more diluted, reducing their local transfection efficiency. Future studies will be required to investigate optimal dosage for anionic formulations. The potential for efficient, targeted gene expression from anionic nanocomplexes combined with their improved distribution by CED suggests their utility for delivery of therapeutic genes to the brain.</ce:para></ce:section><ce:section id="s0110" view="all"><ce:label>5</ce:label><ce:section-title id="st0120">Conclusions</ce:section-title><ce:para id="p0205" view="all">In this study we describe a novel, multifunctional, anionic nanocomplex and demonstrated that optimized PEGylation strategies enhanced transfection efficiency and receptor-targeted specificity, possibly by lowering repulsion forces from the anionic moieties on the cell surfaces. This contrasts with cationic synthetic nanocomplex formulations where PEGylation typically reduces transfection efficiency. Distribution of gadolinium-labeled nanocomplex formulations in brain, administered by direct delivery, was improved in anionic formulations with levels of transfection equivalent to cationic formulations, demonstrating the potential for theranostic delivery of genes and contrast agents to allow monitoring of biodistribution by MRI.</ce:para><ce:para view="extended" id="p0215">The following are the supplementary data related to this article.<ce:display><ce:e-component id="ec0005"><ce:label>Supplementary Table 1</ce:label><ce:caption id="ca0010"><ce:simple-para id="sp0015" view="all">Lipids used to formulate the liposomes and their structures.</ce:simple-para></ce:caption><ce:link locator="mmc1"/></ce:e-component></ce:display><ce:display><ce:figure id="f0005"><ce:label>Fig. 1S</ce:label><ce:caption id="ca0015"><ce:simple-para id="sp0020" view="all">Biophysical and transfection efficiency comparisons show that Method 2 of mixing is better than Method 1. (A) Relative fluorescence unit (RFU) of the DNA complexes as a percentage of signal from free DNA in fluorescence quenching experiments was measured for anionic non-PEGylated nanoparticles that were made at different molar charge ratios and with two different methods of mixing (Method 1 and Method 2). (B) B104 and (C) 16HBE14o- cells were transfected with non-PEGylated anionic nanocomplexes at different molar charge ratios and 24<ce:hsp sp="0.25"/>h later luciferase expression was analyzed. Asterisks indicate comparisons of specific formulations with statistical significance (**, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01; ***, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001). Peptide Y was used for all formulations.</ce:simple-para></ce:caption><ce:link locator="gr7" id="lk0035"/></ce:figure></ce:display><ce:display><ce:figure id="f0010"><ce:label>Fig. 2S</ce:label><ce:caption id="ca0020"><ce:simple-para id="sp0025" view="all">Competitive inhibition of peptide Y-mediated gene delivery by free ligand YL. Cationic LPD nanocomplexes (weight ratio 1:4:1) and aniomic PDL<ce:sup loc="post">AP</ce:sup>2 nanocomplexes at 4:3:1 molar charge ratio made with two different peptides (peptide Y and scrambled peptide PS) were used in luciferase transfections of Neuro-2A cells. Competitive inhibition of peptide Y-mediated gene delivery was performed either in the presence or in the absence of free ligands at a concentration of 100<ce:hsp sp="0.25"/>μm for 90<ce:hsp sp="0.25"/>min prior to the addition of nanocomplexes. The graph shows % of luciferase gene expression relative to LPD (Y) for the cationic nanoparticles and relative to PDL<ce:sup loc="post">AP</ce:sup>2 (Y) for the anionic nanoparticles. Each column represents the mean<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>SD from six wells. Asterisks indicate comparisons of specific formulations with statistical significance (***, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001).</ce:simple-para></ce:caption><ce:link locator="gr8" id="lk0040"/></ce:figure></ce:display><ce:display><ce:figure id="f0045"><ce:label>Fig. 3S</ce:label><ce:caption id="ca1020"><ce:simple-para id="sp1025" view="all">Histological assessment of rhodamine-labeled nanocomplexes in corpus callosum following CED administration <ce:italic>in vivo</ce:italic>. The cationic PEGylated nanoparticles Cat L<ce:sup loc="post">CPRG</ce:sup>PD (a–c) have shown minimal rhodamine spread (a) and GFP transfection (b). In contrast, the Cat PDL<ce:sup loc="post">APRG</ce:sup> nanoparticles (d–f) have shown good rhodamine spread (d) and the Ani PDL<ce:sup loc="post">APRG</ce:sup>nanoparticles (g-i) have also shown good distribution (g) which is similar to the Cat PDL<ce:sup loc="post">APRG</ce:sup> nanoparticles. Rhodamine (a, d and g), GFP (b, e and h) and merged image showing the cellular nature of corpus callosum by DAPI staining (c, f and i). Peptide Y was used for all formulations. Scale bar<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>100<ce:hsp sp="0.25"/>μm.</ce:simple-para></ce:caption><ce:link locator="gr9" id="lk1040"/></ce:figure></ce:display></ce:para><ce:para view="compact-standard" id="p0220">Supplementary data to this article can be found online at <ce:inter-ref xlink:href="doi:10.1016/j.jconrel.2013.11.014" id="ir0005" xlink:type="simple">http://dx.doi.org/10.1016/j.jconrel.2013.11.014</ce:inter-ref>.</ce:para></ce:section></ce:sections><ce:acknowledgment id="ac0005" view="all"><ce:section-title id="st0125">Acknowledgments</ce:section-title><ce:para id="p0210" view="all">This work was funded by the <ce:grant-sponsor id="gts0005" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Engineering and Physical Sciences Research Council (EPSRC</ce:grant-sponsor>; <ce:grant-number refid="gts0005">EP/G061521/1</ce:grant-number>) and by the <ce:grant-sponsor id="gts0010" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Association for International Cancer Research (AICR)</ce:grant-sponsor>. We would like to thank Dr Mauro Botta from the Università del Piemonte Orientale “Amedeo Avogadro” for providing the gadolinium-labeled lipid.</ce:para></ce:acknowledgment></body><tail view="all"><ce:bibliography id="bi0005" view="all"><ce:section-title id="st0130">References</ce:section-title><ce:bibliography-sec id="bs0005" view="all"><ce:bib-reference id="bb0005"><ce:label>[1]</ce:label><sb:reference id="rf0005"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Glover</ce:surname></sb:author><sb:author><ce:given-name>H.J.</ce:given-name><ce:surname>Lipps</ce:surname></sb:author><sb:author><ce:given-name>D.A.</ce:given-name><ce:surname>Jans</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Towards safe, non-viral therapeutic gene expression in humans</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Rev. Genet.</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>299</sb:first-page><sb:last-page>310</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0010"><ce:label>[2]</ce:label><sb:reference id="rf0010"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.D.</ce:given-name><ce:surname>Schmidt-Wolf</ce:surname></sb:author><sb:author><ce:given-name>I.G.</ce:given-name><ce:surname>Schmidt-Wolf</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Non-viral and hybrid vectors in human gene therapy: an update</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Trends Mol. Med.</sb:maintitle></sb:title><sb:volume-nr>9</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>67</sb:first-page><sb:last-page>72</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0015"><ce:label>[3]</ce:label><sb:reference id="rf0015"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>H.M.</ce:given-name><ce:surname>Aliabadi</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Landry</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Sun</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Tang</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Uludag</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Supramolecular assemblies in functional siRNA delivery: where do we stand?</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biomaterials</sb:maintitle></sb:title><sb:volume-nr>33</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>2546</sb:first-page><sb:last-page>2569</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0020"><ce:label>[4]</ce:label><sb:reference id="rf0020"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Elsabahy</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Nazarali</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Foldvari</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Non-viral nucleic acid delivery: key challenges and future directions</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Curr. Drug Deliv.</sb:maintitle></sb:title><sb:volume-nr>8</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>235</sb:first-page><sb:last-page>244</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0025"><ce:label>[5]</ce:label><sb:reference id="rf0025"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Pezzoli</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Chiesa</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>De Nardo</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Candiani</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>We still have a long way to go to effectively deliver genes!</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Appl. Biomater. Funct. Mater.</sb:maintitle></sb:title><sb:volume-nr>10</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>82</sb:first-page><sb:last-page>91</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0030"><ce:label>[6]</ce:label><sb:reference id="rf0030"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Scholz</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Wagner</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Control. Release</sb:maintitle></sb:title><sb:volume-nr>161</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>554</sb:first-page><sb:last-page>565</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0035"><ce:label>[7]</ce:label><sb:reference id="rf0035"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.I.</ce:given-name><ce:surname>Mahato</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Rolland</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Tomlinson</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Cationic lipid-based gene delivery systems: pharmaceutical perspectives</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Pharm. Res.</sb:maintitle></sb:title><sb:volume-nr>14</sb:volume-nr></sb:series><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>853</sb:first-page><sb:last-page>859</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0040"><ce:label>[8]</ce:label><sb:reference id="rf0040"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.A.</ce:given-name><ce:surname>Mintzer</ce:surname></sb:author><sb:author><ce:given-name>E.E.</ce:given-name><ce:surname>Simanek</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Nonviral vectors for gene delivery</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Chem. Rev.</sb:maintitle></sb:title><sb:volume-nr>109</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>259</sb:first-page><sb:last-page>302</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0045"><ce:label>[9]</ce:label><sb:reference id="rf0045"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Li</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Ma</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Steinhoff</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Non-viral gene delivery methods</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Curr. Pharm. Biotechnol.</sb:maintitle></sb:title><sb:volume-nr>14</sb:volume-nr></sb:series><sb:date>2013</sb:date></sb:issue><sb:pages><sb:first-page>46</sb:first-page><sb:last-page>60</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0050"><ce:label>[10]</ce:label><sb:reference id="rf0050"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>F.W.</ce:given-name><ce:surname>Huang</ce:surname></sb:author><sb:author><ce:given-name>H.Y.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Li</ce:surname></sb:author><sb:author><ce:given-name>H.F.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>Y.X.</ce:given-name><ce:surname>Sun</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Feng</ce:surname></sb:author><sb:author><ce:given-name>X.Z.</ce:given-name><ce:surname>Zhang</ce:surname></sb:author><sb:author><ce:given-name>R.X.</ce:given-name><ce:surname>Zhuo</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>PEGylated PEI-based biodegradable polymers as non-viral gene vectors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Acta Biomater.</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>4285</sb:first-page><sb:last-page>4295</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0055"><ce:label>[11]</ce:label><sb:reference id="rf0055"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Mishra</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Webster</ce:surname></sb:author><sb:author><ce:given-name>M.E.</ce:given-name><ce:surname>Davis</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Eur. J. Cell Biol.</sb:maintitle></sb:title><sb:volume-nr>83</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>97</sb:first-page><sb:last-page>111</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0060"><ce:label>[12]</ce:label><sb:reference id="rf0060"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.A.</ce:given-name><ce:surname>Balazs</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Godbey</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Liposomes for use in gene delivery</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Drug Deliv.</sb:maintitle></sb:title><sb:volume-nr>2011</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>326497</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0065"><ce:label>[13]</ce:label><sb:reference id="rf0065"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>N.S.</ce:given-name><ce:surname>Chiaramoni</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Gasparri</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Speroni</ce:surname></sb:author><sb:author><ce:given-name>M.C.</ce:given-name><ce:surname>Taira</ce:surname></sb:author><sb:author><ce:given-name>V.</ce:given-name><ce:surname>Alonso Sdel</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Biodistribution of liposome/DNA systems after subcutaneous and intraperitoneal inoculation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Liposome Res.</sb:maintitle></sb:title><sb:volume-nr>20</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>191</sb:first-page><sb:last-page>201</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0070"><ce:label>[14]</ce:label><sb:reference id="rf0070"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.D.</ce:given-name><ce:surname>Patil</ce:surname></sb:author><sb:author><ce:given-name>D.G.</ce:given-name><ce:surname>Rhodes</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Burgess</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Biophysical characterization of anionic lipoplexes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochim. Biophys. Acta</sb:maintitle></sb:title><sb:volume-nr>1711</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>1</sb:first-page><sb:last-page>11</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0075"><ce:label>[15]</ce:label><sb:reference id="rf0075"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Foged</ce:surname></sb:author><sb:author><ce:given-name>H.M.</ce:given-name><ce:surname>Nielsen</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Frokjaer</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Liposomes for phospholipase A2 triggered siRNA release: preparation and <ce:italic>in vitro</ce:italic> test</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Int. J. Pharm.</sb:maintitle></sb:title><sb:volume-nr>331</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>160</sb:first-page><sb:last-page>166</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0080"><ce:label>[16]</ce:label><sb:reference id="rf0080"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Kapoor</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Burgess</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Physicochemical characterization of anionic lipid-based ternary siRNA complexes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochim. Biophys. Acta</sb:maintitle></sb:title><sb:volume-nr>1818</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>1603</sb:first-page><sb:last-page>1612</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0085"><ce:label>[17]</ce:label><sb:reference id="rf0085"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Li</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Yang</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Huang</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Control. Release</sb:maintitle></sb:title><sb:volume-nr>158</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>108</sb:first-page><sb:last-page>114</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0090"><ce:label>[18]</ce:label><sb:reference id="rf0090"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.D.</ce:given-name><ce:surname>Patil</ce:surname></sb:author><sb:author><ce:given-name>D.G.</ce:given-name><ce:surname>Rhodes</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Burgess</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Anionic liposomal delivery system for DNA transfection</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>AAPS J.</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>13</sb:first-page><sb:last-page>22</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0095"><ce:label>[19]</ce:label><sb:reference id="rf0095"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Srinivasan</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Burgess</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Optimization and characterization of anionic lipoplexes for gene delivery</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Control. Release</sb:maintitle></sb:title><sb:volume-nr>136</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>62</sb:first-page><sb:last-page>70</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0100"><ce:label>[20]</ce:label><sb:reference id="rf0100"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>S.R.</ce:given-name><ce:surname>Bathula</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Li</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Huang</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>285</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>22639</sb:first-page><sb:last-page>22650</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0105"><ce:label>[21]</ce:label><sb:reference id="rf0105"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Sun</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Zhong</ce:surname></sb:author><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Shi</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Li</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Anionic LPD complexes for gene delivery to macrophage: preparation, characterization and transfection <ce:italic>in vitro</ce:italic></sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Drug Target.</sb:maintitle></sb:title><sb:volume-nr>16</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>668</sb:first-page><sb:last-page>678</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0110"><ce:label>[22]</ce:label><sb:reference id="rf0110"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Yuan</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Zhang</ce:surname></sb:author><sb:author><ce:given-name>Y.Z.</ce:given-name><ce:surname>Du</ce:surname></sb:author><sb:author><ce:given-name>F.Q.</ce:given-name><ce:surname>Hu</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Ternary nanoparticles of anionic lipid nanoparticles/protamine/DNA for gene delivery</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Int. J. Pharm.</sb:maintitle></sb:title><sb:volume-nr>392</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>224</sb:first-page><sb:last-page>231</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0115"><ce:label>[23]</ce:label><sb:reference id="rf0115"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.J.</ce:given-name><ce:surname>Harris</ce:surname></sb:author><sb:author><ce:given-name>J.J.</ce:given-name><ce:surname>Green</ce:surname></sb:author><sb:author><ce:given-name>P.W.</ce:given-name><ce:surname>Fung</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Langer</ce:surname></sb:author><sb:author><ce:given-name>D.G.</ce:given-name><ce:surname>Anderson</ce:surname></sb:author><sb:author><ce:given-name>S.N.</ce:given-name><ce:surname>Bhatia</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Tissue-specific gene delivery via nanoparticle coating</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biomaterials</sb:maintitle></sb:title><sb:volume-nr>31</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>998</sb:first-page><sb:last-page>1006</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0120"><ce:label>[24]</ce:label><sb:reference id="rf0120"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Schlegel</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Bigey</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Dhotel</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Scherman</ce:surname></sb:author><sb:author><ce:given-name>V.</ce:given-name><ce:surname>Escriou</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Reduced <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> toxicity of siRNA-lipoplexes with addition of polyglutamate</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Control. Release</sb:maintitle></sb:title><sb:volume-nr>165</sb:volume-nr></sb:series><sb:date>2013</sb:date></sb:issue><sb:pages><sb:first-page>1</sb:first-page><sb:last-page>8</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0125"><ce:label>[25]</ce:label><sb:reference id="rf0125"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Mignet</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Richard</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Seguin</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Largeau</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Bessodes</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Scherman</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Anionic pH-sensitive PEGylated lipoplexes to deliver DNA to tumors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Int. J. Pharm.</sb:maintitle></sb:title><sb:volume-nr>361</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>194</sb:first-page><sb:last-page>201</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0130"><ce:label>[26]</ce:label><sb:reference id="rf0130"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.D.</ce:given-name><ce:surname>Manunta</ce:surname></sb:author><sb:author><ce:given-name>R.J.</ce:given-name><ce:surname>McAnulty</ce:surname></sb:author><sb:author><ce:given-name>A.D.</ce:given-name><ce:surname>Tagalakis</ce:surname></sb:author><sb:author><ce:given-name>S.E.</ce:given-name><ce:surname>Bottoms</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Campbell</ce:surname></sb:author><sb:author><ce:given-name>H.C.</ce:given-name><ce:surname>Hailes</ce:surname></sb:author><sb:author><ce:given-name>A.B.</ce:given-name><ce:surname>Tabor</ce:surname></sb:author><sb:author><ce:given-name>G.J.</ce:given-name><ce:surname>Laurent</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>O'Callaghan</ce:surname></sb:author><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Hart</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Nebulisation of receptor-targeted nanocomplexes for gene delivery to the airway epithelium</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>PLoS One</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>e26768</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0135"><ce:label>[27]</ce:label><sb:reference id="rf0135"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.D.</ce:given-name><ce:surname>Tagalakis</ce:surname></sb:author><sb:author><ce:given-name>R.J.</ce:given-name><ce:surname>McAnulty</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Devaney</ce:surname></sb:author><sb:author><ce:given-name>S.E.</ce:given-name><ce:surname>Bottoms</ce:surname></sb:author><sb:author><ce:given-name>J.B.</ce:given-name><ce:surname>Wong</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Elbs</ce:surname></sb:author><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Writer</ce:surname></sb:author><sb:author><ce:given-name>H.C.</ce:given-name><ce:surname>Hailes</ce:surname></sb:author><sb:author><ce:given-name>A.B.</ce:given-name><ce:surname>Tabor</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>O'Callaghan</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Jaffe</ce:surname></sb:author><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Hart</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A receptor-targeted nanocomplex vector system optimized for respiratory gene transfer</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mol. Ther.</sb:maintitle></sb:title><sb:volume-nr>16</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>907</sb:first-page><sb:last-page>915</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0140"><ce:label>[28]</ce:label><sb:reference id="rf0140"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.M.</ce:given-name><ce:surname>Grosse</ce:surname></sb:author><sb:author><ce:given-name>A.D.</ce:given-name><ce:surname>Tagalakis</ce:surname></sb:author><sb:author><ce:given-name>M.F.</ce:given-name><ce:surname>Mustapa</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Elbs</ce:surname></sb:author><sb:author><ce:given-name>Q.H.</ce:given-name><ce:surname>Meng</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Mohammadi</ce:surname></sb:author><sb:author><ce:given-name>A.B.</ce:given-name><ce:surname>Tabor</ce:surname></sb:author><sb:author><ce:given-name>H.C.</ce:given-name><ce:surname>Hailes</ce:surname></sb:author><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Hart</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Tumor-specific gene transfer with receptor-mediated nanocomplexes modified by polyethylene glycol shielding and endosomally cleavable lipid and peptide linkers</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>FASEB J.</sb:maintitle></sb:title><sb:volume-nr>24</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>2301</sb:first-page><sb:last-page>2313</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0145"><ce:label>[29]</ce:label><sb:reference id="rf0145"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.D.</ce:given-name><ce:surname>Kenny</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Villegas-Llerena</ce:surname></sb:author><sb:author><ce:given-name>A.D.</ce:given-name><ce:surname>Tagalakis</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Campbell</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Welser</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Botta</ce:surname></sb:author><sb:author><ce:given-name>A.B.</ce:given-name><ce:surname>Tabor</ce:surname></sb:author><sb:author><ce:given-name>H.C.</ce:given-name><ce:surname>Hailes</ce:surname></sb:author><sb:author><ce:given-name>M.F.</ce:given-name><ce:surname>Lythgoe</ce:surname></sb:author><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Hart</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Multifunctional receptor-targeted nanocomplexes for magnetic resonance imaging and transfection of tumours</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biomaterials</sb:maintitle></sb:title><sb:volume-nr>33</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>7241</sb:first-page><sb:last-page>7250</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0150"><ce:label>[30]</ce:label><sb:reference id="rf0150"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.D.</ce:given-name><ce:surname>Tagalakis</ce:surname></sb:author><sb:author><ce:given-name>S.M.</ce:given-name><ce:surname>Grosse</ce:surname></sb:author><sb:author><ce:given-name>Q.H.</ce:given-name><ce:surname>Meng</ce:surname></sb:author><sb:author><ce:given-name>M.F.</ce:given-name><ce:surname>Mustapa</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Kwok</ce:surname></sb:author><sb:author><ce:given-name>S.E.</ce:given-name><ce:surname>Salehi</ce:surname></sb:author><sb:author><ce:given-name>A.B.</ce:given-name><ce:surname>Tabor</ce:surname></sb:author><sb:author><ce:given-name>H.C.</ce:given-name><ce:surname>Hailes</ce:surname></sb:author><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Hart</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biomaterials</sb:maintitle></sb:title><sb:volume-nr>32</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>1370</sb:first-page><sb:last-page>1376</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0155"><ce:label>[31]</ce:label><sb:reference id="rf0155"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Irvine</ce:surname></sb:author><sb:author><ce:given-name>Q.H.</ce:given-name><ce:surname>Meng</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Afzal</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Ho</ce:surname></sb:author><sb:author><ce:given-name>J.B.</ce:given-name><ce:surname>Wong</ce:surname></sb:author><sb:author><ce:given-name>H.C.</ce:given-name><ce:surname>Hailes</ce:surname></sb:author><sb:author><ce:given-name>A.B.</ce:given-name><ce:surname>Tabor</ce:surname></sb:author><sb:author><ce:given-name>J.R.</ce:given-name><ce:surname>McEwan</ce:surname></sb:author><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Hart</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Receptor-targeted nanocomplexes optimized for gene transfer to primary vascular cells and explant cultures of rabbit aorta</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mol. Ther.</sb:maintitle></sb:title><sb:volume-nr>16</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>508</sb:first-page><sb:last-page>515</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0160"><ce:label>[32]</ce:label><sb:reference id="rf0160"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Q.H.</ce:given-name><ce:surname>Meng</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Irvine</ce:surname></sb:author><sb:author><ce:given-name>A.D.</ce:given-name><ce:surname>Tagalakis</ce:surname></sb:author><sb:author><ce:given-name>R.J.</ce:given-name><ce:surname>McAnulty</ce:surname></sb:author><sb:author><ce:given-name>J.R.</ce:given-name><ce:surname>McEwan</ce:surname></sb:author><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Hart</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Inhibition of neointimal hyperplasia in a rabbit vein graft model following non-viral transfection with human iNOS cDNA</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Gene Ther.</sb:maintitle></sb:title><sb:volume-nr>20</sb:volume-nr></sb:series><sb:date>2013</sb:date></sb:issue><sb:pages><sb:first-page>979</sb:first-page><sb:last-page>986</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0165"><ce:label>[33]</ce:label><sb:reference id="rf0165"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.D.</ce:given-name><ce:surname>Kenny</ce:surname></sb:author><sb:author><ce:given-name>A.S.</ce:given-name><ce:surname>Bienemann</ce:surname></sb:author><sb:author><ce:given-name>A.D.</ce:given-name><ce:surname>Tagalakis</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Pugh</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Welser</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Campbell</ce:surname></sb:author><sb:author><ce:given-name>A.B.</ce:given-name><ce:surname>Tabor</ce:surname></sb:author><sb:author><ce:given-name>H.C.</ce:given-name><ce:surname>Hailes</ce:surname></sb:author><sb:author><ce:given-name>S.S.</ce:given-name><ce:surname>Gill</ce:surname></sb:author><sb:author><ce:given-name>M.F.</ce:given-name><ce:surname>Lythgoe</ce:surname></sb:author><sb:author><ce:given-name>C.W.</ce:given-name><ce:surname>McLeod</ce:surname></sb:author><sb:author><ce:given-name>E.A.</ce:given-name><ce:surname>White</ce:surname></sb:author><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Hart</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Multifunctional receptor-targeted nanocomplexes for the delivery of therapeutic nucleic acids to the brain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biomaterials</sb:maintitle></sb:title><sb:volume-nr>34</sb:volume-nr></sb:series><sb:date>2013</sb:date></sb:issue><sb:pages><sb:first-page>9190</sb:first-page><sb:last-page>9200</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0170"><ce:label>[34]</ce:label><sb:reference id="rf0170"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.D.</ce:given-name><ce:surname>Tagalakis</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>He</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Saraiva</ce:surname></sb:author><sb:author><ce:given-name>K.T.</ce:given-name><ce:surname>Gustafsson</ce:surname></sb:author><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Hart</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biomaterials</sb:maintitle></sb:title><sb:volume-nr>32</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>6302</sb:first-page><sb:last-page>6315</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0175"><ce:label>[35]</ce:label><sb:reference id="rf0175"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Writer</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Marshall</ce:surname></sb:author><sb:author><ce:given-name>M.A.</ce:given-name><ce:surname>Pilkington-Miksa</ce:surname></sb:author><sb:author><ce:given-name>S.E.</ce:given-name><ce:surname>Barker</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Jacobsen</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Kritz</ce:surname></sb:author><sb:author><ce:given-name>P.C.</ce:given-name><ce:surname>Bell</ce:surname></sb:author><sb:author><ce:given-name>D.H.</ce:given-name><ce:surname>Lester</ce:surname></sb:author><sb:author><ce:given-name>A.B.</ce:given-name><ce:surname>Tabor</ce:surname></sb:author><sb:author><ce:given-name>H.C.</ce:given-name><ce:surname>Hailes</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Klein</ce:surname></sb:author><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Hart</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Targeted gene delivery to human airway epithelial cells with synthetic vectors incorporating novel targeting peptides selected by phage display</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Drug Target.</sb:maintitle></sb:title><sb:volume-nr>12</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>185</sb:first-page><sb:last-page>193</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0180"><ce:label>[36]</ce:label><sb:reference id="rf0180"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.D.</ce:given-name><ce:surname>Tagalakis</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Saraiva</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>McCarthy</ce:surname></sb:author><sb:author><ce:given-name>K.T.</ce:given-name><ce:surname>Gustafsson</ce:surname></sb:author><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Hart</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Comparison of nanocomplexes with branched and linear peptides for siRNA delivery</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biomacromolecules</sb:maintitle></sb:title><sb:volume-nr>14</sb:volume-nr></sb:series><sb:date>2013</sb:date></sb:issue><sb:pages><sb:first-page>761</sb:first-page><sb:last-page>770</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0185"><ce:label>[37]</ce:label><sb:reference id="rf0185"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.H.</ce:given-name><ce:surname>Bobo</ce:surname></sb:author><sb:author><ce:given-name>D.W.</ce:given-name><ce:surname>Laske</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Akbasak</ce:surname></sb:author><sb:author><ce:given-name>P.F.</ce:given-name><ce:surname>Morrison</ce:surname></sb:author><sb:author><ce:given-name>R.L.</ce:given-name><ce:surname>Dedrick</ce:surname></sb:author><sb:author><ce:given-name>E.H.</ce:given-name><ce:surname>Oldfield</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Convection-enhanced delivery of macromolecules in the brain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle></sb:title><sb:volume-nr>91</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>2076</sb:first-page><sb:last-page>2080</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0190"><ce:label>[38]</ce:label><sb:reference id="rf0190"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>B.S.</ce:given-name><ce:surname>Carson</ce:surname><ce:suffix>Sr.</ce:suffix></sb:author><sb:author><ce:given-name>Q.</ce:given-name><ce:surname>Wu</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Tyler</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Sukay</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Raychaudhuri</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>DiMeco</ce:surname></sb:author><sb:author><ce:given-name>R.E.</ce:given-name><ce:surname>Clatterbuck</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Olivi</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Guarnieri</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>New approach to tumor therapy for inoperable areas of the brain: chronic intraparenchymal drug delivery</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurooncol.</sb:maintitle></sb:title><sb:volume-nr>60</sb:volume-nr></sb:series><sb:date>2002</sb:date></sb:issue><sb:pages><sb:first-page>151</sb:first-page><sb:last-page>158</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0195"><ce:label>[39]</ce:label><sb:reference id="rf0195"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.S.</ce:given-name><ce:surname>Gill</ce:surname></sb:author><sb:author><ce:given-name>N.K.</ce:given-name><ce:surname>Patel</ce:surname></sb:author><sb:author><ce:given-name>G.R.</ce:given-name><ce:surname>Hotton</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>O'Sullivan</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>McCarter</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Bunnage</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Brooks</ce:surname></sb:author><sb:author><ce:given-name>C.N.</ce:given-name><ce:surname>Svendsen</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Heywood</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Med.</sb:maintitle></sb:title><sb:volume-nr>9</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>589</sb:first-page><sb:last-page>595</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0200"><ce:label>[40]</ce:label><sb:reference id="rf0200"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.R.</ce:given-name><ce:surname>Groothuis</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Ward</ce:surname></sb:author><sb:author><ce:given-name>A.C.</ce:given-name><ce:surname>Itskovich</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Dobrescu</ce:surname></sb:author><sb:author><ce:given-name>C.V.</ce:given-name><ce:surname>Allen</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Dills</ce:surname></sb:author><sb:author><ce:given-name>R.M.</ce:given-name><ce:surname>Levy</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Comparison of 14C-sucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurosurg.</sb:maintitle></sb:title><sb:volume-nr>90</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>321</sb:first-page><sb:last-page>331</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0205"><ce:label>[41]</ce:label><sb:reference id="rf0205"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Mardor</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Roth</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Lidar</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Jonas</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Pfeffer</ce:surname></sb:author><sb:author><ce:given-name>S.E.</ce:given-name><ce:surname>Maier</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Faibel</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Nass</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Hadani</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Orenstein</ce:surname></sb:author><sb:author><ce:given-name>J.S.</ce:given-name><ce:surname>Cohen</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Ram</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cancer Res.</sb:maintitle></sb:title><sb:volume-nr>61</sb:volume-nr></sb:series><sb:date>2001</sb:date></sb:issue><sb:pages><sb:first-page>4971</sb:first-page><sb:last-page>4973</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0210"><ce:label>[42]</ce:label><sb:reference id="rf0210"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Voges</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Reszka</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Gossmann</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Dittmar</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Richter</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Garlip</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Kracht</ce:surname></sb:author><sb:author><ce:given-name>H.H.</ce:given-name><ce:surname>Coenen</ce:surname></sb:author><sb:author><ce:given-name>V.</ce:given-name><ce:surname>Sturm</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Wienhard</ce:surname></sb:author><sb:author><ce:given-name>W.D.</ce:given-name><ce:surname>Heiss</ce:surname></sb:author><sb:author><ce:given-name>A.H.</ce:given-name><ce:surname>Jacobs</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>54</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>479</sb:first-page><sb:last-page>487</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0215"><ce:label>[43]</ce:label><sb:reference id="rf0215"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.</ce:given-name><ce:surname>White</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Bienemann</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Sena-Esteves</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Taylor</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Bunnun</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Castrique</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Gill</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Evaluation and optimization of the administration of recombinant adeno-associated viral vectors (serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10) by convection-enhanced delivery to the striatum</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Hum. Gene Ther.</sb:maintitle></sb:title><sb:volume-nr>22</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>237</sb:first-page><sb:last-page>251</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0220"><ce:label>[44]</ce:label><sb:reference id="rf0220"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Kielar</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Tei</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Terreno</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Botta</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Large relaxivity enhancement of paramagnetic lipid nanoparticles by restricting the local motions of the Gd(III) chelates</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Am. Chem. Soc.</sb:maintitle></sb:title><sb:volume-nr>132</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>7836</sb:first-page><sb:last-page>7837</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0225"><ce:label>[45]</ce:label><sb:reference id="rf0225"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>P.J.</ce:given-name><ce:surname>Jost</ce:surname></sb:author><sb:author><ce:given-name>R.P.</ce:given-name><ce:surname>Harbottle</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Knight</ce:surname></sb:author><sb:author><ce:given-name>A.D.</ce:given-name><ce:surname>Miller</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Coutelle</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Schneider</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A novel peptide, THALWHT, for the targeting of human airway epithelia</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>FEBS Lett.</sb:maintitle></sb:title><sb:volume-nr>489</sb:volume-nr></sb:series><sb:date>2001</sb:date></sb:issue><sb:pages><sb:first-page>263</sb:first-page><sb:last-page>269</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0230"><ce:label>[46]</ce:label><sb:reference id="rf0230"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Zhang</ce:surname></sb:author><sb:author><ce:given-name>T.J.</ce:given-name><ce:surname>Anchordoquy</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The role of lipid charge density in the serum stability of cationic lipid/DNA complexes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochim. Biophys. Acta</sb:maintitle></sb:title><sb:volume-nr>1663</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>143</sb:first-page><sb:last-page>157</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0235"><ce:label>[47]</ce:label><sb:reference id="rf0235"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.G.</ce:given-name><ce:surname>Penfield</ce:surname></sb:author><sb:author><ce:given-name>R.F.</ce:given-name><ce:surname>Reilly</ce:surname><ce:suffix>Jr.</ce:suffix></sb:author></sb:authors><sb:title><sb:maintitle>What nephrologists need to know about gadolinium</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Clin. Pract. Nephrol.</sb:maintitle></sb:title><sb:volume-nr>3</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>654</sb:first-page><sb:last-page>668</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0240"><ce:label>[48]</ce:label><sb:reference id="rf0240"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.J.</ce:given-name><ce:surname>Lee</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Huang</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>271</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>8481</sb:first-page><sb:last-page>8487</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0245"><ce:label>[49]</ce:label><sb:reference id="rf0245"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.L.</ce:given-name><ce:surname>Lorenzi</ce:surname></sb:author><sb:author><ce:given-name>K.D.</ce:given-name><ce:surname>Lee</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Enhanced plasmid DNA delivery using anionic LPDII by listeriolysin O incorporation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Gene Med.</sb:maintitle></sb:title><sb:volume-nr>7</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>1077</sb:first-page><sb:last-page>1085</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0250"><ce:label>[50]</ce:label><sb:reference id="rf0250"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Sun</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Zhang</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Optimizing the novel formulation of liposome-polycation-DNA complexes (LPD) by central composite design</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Arch. Pharm. Res.</sb:maintitle></sb:title><sb:volume-nr>27</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>797</sb:first-page><sb:last-page>805</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0255"><ce:label>[51]</ce:label><sb:reference id="rf0255"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Ye</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Liu</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Zhang</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Anionic solid lipid nanoparticles supported on protamine/DNA complexes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nanotechnology</sb:maintitle></sb:title><sb:volume-nr>19</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>285708</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0260"><ce:label>[52]</ce:label><sb:reference id="rf0260"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.J.</ce:given-name><ce:surname>Green</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Chiu</ce:surname></sb:author><sb:author><ce:given-name>E.S.</ce:given-name><ce:surname>Leshchiner</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Shi</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Langer</ce:surname></sb:author><sb:author><ce:given-name>D.G.</ce:given-name><ce:surname>Anderson</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Electrostatic ligand coatings of nanoparticles enable ligand-specific gene delivery to human primary cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nano Lett.</sb:maintitle></sb:title><sb:volume-nr>7</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>874</sb:first-page><sb:last-page>879</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0265"><ce:label>[53]</ce:label><sb:reference id="rf0265"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>He</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Cheng</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Xie</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Nie</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>He</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Gu</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Polyethyleneimine/DNA polyplexes with reduction-sensitive hyaluronic acid derivatives shielding for targeted gene delivery</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biomaterials</sb:maintitle></sb:title><sb:volume-nr>34</sb:volume-nr></sb:series><sb:date>2013</sb:date></sb:issue><sb:pages><sb:first-page>1235</sb:first-page><sb:last-page>1245</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0270"><ce:label>[54]</ce:label><sb:reference id="rf0270"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Z.X.</ce:given-name><ce:surname>Liao</ce:surname></sb:author><sb:author><ce:given-name>S.F.</ce:given-name><ce:surname>Peng</ce:surname></sb:author><sb:author><ce:given-name>Y.C.</ce:given-name><ce:surname>Ho</ce:surname></sb:author><sb:author><ce:given-name>F.L.</ce:given-name><ce:surname>Mi</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Maiti</ce:surname></sb:author><sb:author><ce:given-name>H.W.</ce:given-name><ce:surname>Sung</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mechanistic study of transfection of chitosan/DNA complexes coated by anionic poly(gamma-glutamic acid)</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biomaterials</sb:maintitle></sb:title><sb:volume-nr>33</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>3306</sb:first-page><sb:last-page>3315</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0275"><ce:label>[55]</ce:label><sb:reference id="rf0275"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Tian</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Lin</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>T.G.</ce:given-name><ce:surname>Park</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Maruyama</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>RGD targeting hyaluronic acid coating system for PEI-PBLG polycation gene carriers</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Control. Release</sb:maintitle></sb:title><sb:volume-nr>155</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>47</sb:first-page><sb:last-page>53</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0280"><ce:label>[56]</ce:label><sb:reference id="rf0280"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>MacKay</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Li</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Huang</ce:surname></sb:author><sb:author><ce:given-name>E.E.</ce:given-name><ce:surname>Dy</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Huynh</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Tihan</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Collins</ce:surname></sb:author><sb:author><ce:given-name>D.F.</ce:given-name><ce:surname>Deen</ce:surname></sb:author><sb:author><ce:given-name>F.C.</ce:given-name><ce:surname>Szoka</ce:surname><ce:suffix>Jr.</ce:suffix></sb:author></sb:authors><sb:title><sb:maintitle>HIV TAT peptide modifies the distribution of DNA nanolipoparticles following convection-enhanced delivery</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mol. Ther.</sb:maintitle></sb:title><sb:volume-nr>16</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>893</sb:first-page><sb:last-page>900</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0285"><ce:label>[57]</ce:label><sb:reference id="rf0285"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Kapoor</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Burgess</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Cellular uptake mechanisms of novel anionic siRNA lipoplexes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Pharm. Res.</sb:maintitle></sb:title><sb:volume-nr>30</sb:volume-nr></sb:series><sb:date>2013</sb:date></sb:issue><sb:pages><sb:first-page>1161</sb:first-page><sb:last-page>1175</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0290"><ce:label>[58]</ce:label><sb:reference id="rf0290"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Lavigne</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Slater</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Gajanayaka</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Duguay</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Arnau Peyrotte</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Fortier</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Simard</ce:surname></sb:author><sb:author><ce:given-name>A.J.</ce:given-name><ce:surname>Kell</ce:surname></sb:author><sb:author><ce:given-name>M.L.</ce:given-name><ce:surname>Barnes</ce:surname></sb:author><sb:author><ce:given-name>A.R.</ce:given-name><ce:surname>Thierry</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Influence of lipoplex surface charge on siRNA delivery: application to the <ce:italic>in vitro</ce:italic> downregulation of CXCR4 HIV-1 co-receptor</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Expert. Opin. Biol. Ther.</sb:maintitle></sb:title><sb:volume-nr>13</sb:volume-nr></sb:series><sb:date>2013</sb:date></sb:issue><sb:pages><sb:first-page>973</sb:first-page><sb:last-page>985</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0295"><ce:label>[59]</ce:label><sb:reference id="rf0295"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.P.</ce:given-name><ce:surname>Yang</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Huang</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Overcoming the inhibitory effect of serum on lipofection by increasing the charge ratio of cationic liposome to DNA</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Gene Ther.</sb:maintitle></sb:title><sb:volume-nr>4</sb:volume-nr></sb:series><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>950</sb:first-page><sb:last-page>960</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0300"><ce:label>[60]</ce:label><sb:reference id="rf0300"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>P.R.</ce:given-name><ce:surname>Cullis</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Chonn</ce:surname></sb:author><sb:author><ce:given-name>S.C.</ce:given-name><ce:surname>Semple</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour <ce:italic>in vivo</ce:italic></sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Adv. Drug Deliv. Rev.</sb:maintitle></sb:title><sb:volume-nr>32</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>3</sb:first-page><sb:last-page>17</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0305"><ce:label>[61]</ce:label><sb:reference id="rf0305"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.A.</ce:given-name><ce:surname>Bellavance</ce:surname></sb:author><sb:author><ce:given-name>M.B.</ce:given-name><ce:surname>Poirier</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Fortin</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Uptake and intracellular release kinetics of liposome formulations in glioma cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Int. J. Pharm.</sb:maintitle></sb:title><sb:volume-nr>395</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>251</sb:first-page><sb:last-page>259</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0310"><ce:label>[62]</ce:label><sb:reference id="rf0310"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>W.M.</ce:given-name><ce:surname>Li</ce:surname></sb:author><sb:author><ce:given-name>L.D.</ce:given-name><ce:surname>Mayer</ce:surname></sb:author><sb:author><ce:given-name>M.B.</ce:given-name><ce:surname>Bally</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Pharmacol. Exp. Ther.</sb:maintitle></sb:title><sb:volume-nr>300</sb:volume-nr></sb:series><sb:date>2002</sb:date></sb:issue><sb:pages><sb:first-page>976</sb:first-page><sb:last-page>983</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0315"><ce:label>[63]</ce:label><sb:reference id="rf0315"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>MacKay</ce:surname></sb:author><sb:author><ce:given-name>D.F.</ce:given-name><ce:surname>Deen</ce:surname></sb:author><sb:author><ce:given-name>F.C.</ce:given-name><ce:surname>Szoka</ce:surname><ce:suffix>Jr.</ce:suffix></sb:author></sb:authors><sb:title><sb:maintitle>Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Res.</sb:maintitle></sb:title><sb:volume-nr>1035</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>139</sb:first-page><sb:last-page>153</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></tail></article></xocs:serial-item></xocs:doc></originalText></full-text-retrieval-response>